<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Protease‐modulating matrix treatments for healing venous leg ulcers - Westby, MJ - 2016 | Cochrane Library</title> <meta content="Protease‐modulating matrix treatments for healing venous leg ulcers - Westby, MJ - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011918.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Protease‐modulating matrix treatments for healing venous leg ulcers - Westby, MJ - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011918.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011918.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Protease‐modulating matrix treatments for healing venous leg ulcers" name="citation_title"/> <meta content="Maggie J Westby" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="maggie.westby@manchester.ac.uk" name="citation_author_email"/> <meta content="Gill Norman" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="Jo C Dumville" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="Nikki Stubbs" name="citation_author"/> <meta content="Leeds Community Healthcare NHS Trust, St Mary's Hospital" name="citation_author_institution"/> <meta content="Nicky Cullum" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011918.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011918.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011918.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011918.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Bandages; *Wound Healing; Alginates [therapeutic use]; Bandages, Hydrocolloid; Cellulose [therapeutic use]; Collagen [therapeutic use]; Gels [therapeutic use]; Peptide Hydrolases [*metabolism]; Randomized Controlled Trials as Topic; Silver [*therapeutic use]; Time Factors; Varicose Ulcer [*enzymology, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011918.pub2&amp;doi=10.1002/14651858.CD011918.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011918\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011918\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011918.pub2",title:"Protease\\u2010modulating matrix treatments for healing venous leg ulcers",firstPublishedDate:"Dec 15, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011918.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011918.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011918.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011918.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011918.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011918.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011918.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011918.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011918.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011918.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2979 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011918.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/appendices#CD011918-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/table_n/CD011918StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/table_n/CD011918StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Protease‐modulating matrix treatments for healing venous leg ulcers</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#CD011918-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Maggie J Westby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#CD011918-cr-0003">Gill Norman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#CD011918-cr-0004">Jo C Dumville</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#CD011918-cr-0005">Nikki Stubbs</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information#CD011918-cr-0006">Nicky Cullum</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information/en#CD011918-sec-0141">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011918.pub2">https://doi.org/10.1002/14651858.CD011918.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011918-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011918-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011918-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011918-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011918-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011918-abs-0001" lang="en"> <section id="CD011918-sec-0001"> <h3 class="title" id="CD011918-sec-0001">Background</h3> <p>Venous leg ulcers (VLUs) are open skin wounds on the lower leg that occur because of poor blood flow in the veins of the leg; leg ulcers can last from weeks to years, and are both painful and costly. Prevalence in the UK is about 2.9 cases per 10,000 people. First‐line treatment for VLUs is compression therapy, but around 60% of people have unhealed ulcers after 12 weeks' treatment and about 40% after 24 weeks; therefore, there is scope for further improvement. Limited evidence suggests non‐healing leg ulcers may have persisting elevated levels of proteases, which is thought to deter the later stages of healing; thus, timely protease‐modulating matrix (PMM) treatments may improve healing by physically removing proteases from the wound fluid. </p> </section> <section id="CD011918-sec-0002"> <h3 class="title" id="CD011918-sec-0002">Objectives</h3> <p>To determine the effects of protease‐modulating matrix (PMM) treatments on the healing of venous leg ulcers, in people managed in any care setting. </p> </section> <section id="CD011918-sec-0003"> <h3 class="title" id="CD011918-sec-0003">Search methods</h3> <p>In September 2016 we searched: the Cochrane Wounds Specialised Register; CENTRAL; Ovid MEDLINE; Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta‐analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. </p> </section> <section id="CD011918-sec-0004"> <h3 class="title" id="CD011918-sec-0004">Selection criteria</h3> <p>We searched for published or unpublished randomised controlled trials (RCTs) that evaluated PMM treatments for VLUs. We defined PMM treatments as those with a purposeful intent of reducing proteases. Wound healing was the primary endpoint. </p> </section> <section id="CD011918-sec-0005"> <h3 class="title" id="CD011918-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed study selection, risk of bias assessment and data extraction. </p> </section> <section id="CD011918-sec-0006"> <h3 class="title" id="CD011918-sec-0006">Main results</h3> <p>We included 12 studies (784 participants) in this review; sample sizes ranged from 10 to 187 participants (median 56.5). One study had three arms that were all relevant to this review and all the other studies had two arms. One study was a within‐participant comparison. All studies were industry funded. Two studies provided unpublished data for healing. </p> <p>Nine of the included studies compared PMM treatments with other treatments and reported results for the primary outcomes. All treatments were dressings. All studies also gave the participants compression bandaging. Seven of these studies were in participants described as having 'non‐responsive' or 'hard‐to‐heal' ulcers. Results, reported at short, medium and long durations and as time‐to‐event data, are summarised for the comparison of any dressing regimen incorporating PMM versus any other dressing regimen. The majority of the evidence was of low or very low certainty, and was mainly downgraded for risk of bias and imprecision. </p> <p>It is uncertain whether PMM dressing regimens heal VLUs quicker than non‐PMM dressing regimens (low‐certainty evidence from 1 trial with 100 participants) (HR 1.21, 95% CI 0.74 to 1.97). </p> <p>In the short term (four to eight weeks) it is unclear whether there is a difference between PMM dressing regimens and non‐PMM dressing regimens in the probability of healing (very low‐certainty evidence, 2 trials involving 207 participants). </p> <p>In the medium term (12 weeks), it is unclear whether PMM dressing regimens increase the probability of healing compared with non‐PMM dressing regimens (low‐certainty evidence from 4 trials with 192 participants) (RR 1.28, 95% CI 0.95 to 1.71). Over the longer term (6 months), it is also unclear whether there is a difference between PMM dressing regimens and non‐PMM dressing regimens in the probability of healing (low certainty evidence, 1 trial, 100 participants) (RR 1.06, 95% CI 0.80 to 1.41). </p> <p>It is uncertain whether there is a difference in adverse events between PMM dressing regimens and non‐PMM dressing regimens (low‐certainty evidence from 5 trials, 363 participants) (RR 1.03, 95% CI 0.75 to 1.42). It is also unclear whether resource use is lower for PMM dressing regimens (low‐certainty evidence, 1 trial involving 73 participants), or whether mean total costs in a German healthcare setting are different (low‐certainty evidence, 1 trial in 187 participants). One cost‐effectiveness analysis was not included because effectiveness was not based on complete healing. </p> </section> <section id="CD011918-sec-0007"> <h3 class="title" id="CD011918-sec-0007">Authors' conclusions</h3> <p>The evidence is generally of low certainty, particularly because of risk of bias and imprecision of effects. Within these limitations, we are unclear whether PMM dressing regimens influence venous ulcer healing relative to dressing regimens without PMM activity. It is also unclear whether there is a difference in rates of adverse events between PMM and non‐PMM treatments. It is uncertain whether either resource use (products and staff time) or total costs associated with PMM dressing regimens are different from those for non‐PMM dressing regimens. More research is needed to clarify the impact of PMM treatments on venous ulcer healing. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011918-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011918-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011918-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011918-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011918-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011918-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011918-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011918-abs-0004" lang="en"> <h3>Protease‐modulating matrix treatments for healing venous leg ulcers</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effects of treatments designed to lower the levels of protease in venous leg ulcers. Protease is an enzyme, a chemical produced by the body. High levels of protease in a wound are thought to slow down wound healing. We wanted to find out if treatments that remove protease from wounds could help venous leg ulcers to heal more quickly, and if these treatments were harmful in any way. </p> <p><b>Background</b> </p> <p>Venous leg ulcers are open skin wounds on the lower leg that can last weeks, months or even years. Leg ulcers can be painful, may become infected, and may affect mobility and quality of life. In 2012 in the UK, it cost about GBP 1700 per year to treat each person with an open venous leg ulcer. </p> <p>The usual treatment for venous leg ulcers is compression therapy (for example, compression bandages), but even this does not work for everyone (about a third of people still have wounds that have not healed after six months). Therefore, we need to try additional treatments, and various dressings have been used alongside compression therapy. One of these is a 'protease‐modulating matrix' (PMM) type of dressing. Research suggests that wounds are slow to heal when there are high levels of a substance called 'protease'. The PMM dressing is designed to remove these proteases from wound fluid, and this is expected to help the wound heal. </p> <p>In this study, we investigated whether there is any evidence that PMM dressings heal leg ulcers more quickly than other types of dressings. </p> <p><b>Study characteristics</b> </p> <p>In September 2016 we searched for as many relevant studies as we could find that had a reliable design (randomised controlled trials) and had compared PMM treatments with other treatments for venous leg ulcers. We found 12 studies involving a total of 784 people. Ten studies gave results we could use and all treatments were dressings. All these studies gave all the participants compression therapy as well as the dressings. Most of the people in the trials had wounds that were not getting better or had been there a long time. </p> <p><b>Key results</b> </p> <p>Findings from four trials are unclear as to whether there is a benefit of PMM dressings on venous ulcer healing compared with other dressings. Five trials reported on wound side effects and their results are unclear as to whether there is a difference in rates of side effects between PMM dressings and other dressings. It is also unclear whether PMM dressings result in decreases in the amount of saline used and the time taken during dressing changes, and whether there is an effect on total costs. </p> <p><b>Certainty of the evidence</b> <br/> Overall, the certainty of the evidence was judged to be low: most studies we found were small and could have been better conducted, so it was difficult to be sure how meaningful the results were. The next step would be to do more research of better quality to see whether PMM dressings do heal venous ulcers more quickly than other dressings. </p> <p>This plain language summary is up to date as of September 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011918-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011918-sec-0105"></div> <h3 class="title" id="CD011918-sec-0106">Implications for practice</h3> <section id="CD011918-sec-0106"> <p>Low‐certainty evidence in participants with hard‐to‐heal VLUs is unclear whether the use of PMM dressing regimens (in comparison with other dressings), over and above the effect of compression bandaging, increases either the speed of healing or the rate of healing at short‐, medium‐ and long‐term follow‐up. Low‐certainty evidence is unclear whether there is a difference in adverse events compared with other (non‐PMM) dressings, and there is also uncertainty around whether there is a difference in resource use or costs for PMM dressings. </p> <p>The GRADE meaning of 'low‐certainty evidence' is that "our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect". Additionally, "further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate" (<a href="./references#CD011918-bbs2-0076" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64:401‐6. ">Balshem 2011</a>). Further research is proposed (see <a href="#CD011918-sec-0107">Implications for research</a>), but clinicians wishing to use these products should be aware of the uncertainty around the findings of this review. </p> </section> <h3 class="title" id="CD011918-sec-0107">Implications for research</h3> <section id="CD011918-sec-0107"> <p>The findings of this review are that it is uncertain whether PMM treatments result in quicker and more healing for people with hard‐to‐heal VLUs, who are receiving compression treatment, but the limited evidence suggests a possibility that they might. If this is true, such that PMM dressings can give healing times that are shorter by a few weeks compared to other dressings or there is a moderate improvement in the probability of medium term healing, this could be important to patients. The existing evidence is uncertain and so there is a need for further investigation in a large RCT. Such a trial could usefully compare two different PMM dressings and an advanced dressing: two PMM dressings are proposed because we cannot be sure there is a class effect. We suggest the PMM dressings should be those specifically designed and marketed as protease‐modulating (e.g. Promogran and UrgoStart). The population would be people with hard‐to‐heal VLUs or it might be useful to include both venous and mixed venous‐arterial ulcers, as stratified groups. Healing should be investigated as a time‐to‐event outcome, with regular monitoring times and at least six months' follow‐up. It might be useful to additionally monitor protease levels. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011918-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011918-sec-0022"></div> <div class="table" id="CD011918-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Protease‐modulating matrix dressing regimen compared to any other dressing regimen for healing venous leg ulcers</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Protease‐modulating matrix dressing compared to advanced dressings/no dressing for venous leg ulcers</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with venous leg ulcers<br/> <b>Intervention:</b> PMM dressing regimen<br/> <b>Comparison:</b> other dressing regimen; different comparators across studies </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Absolute effect<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other dressing regimen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PMM dressing regimen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>TIme to complete healing</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Estimated median time to complete healing: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Estimated median time to complete healing: 4.5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.21<br/> (0.74 to 1.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>100<br/> (1 RCT<sup>ǂ</sup>) </p> <p>66 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Difference in estimated median time to complete healing: approximately 1.5 months shorter</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants healed ‐ short term (4‐8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>287 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>210 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/> (0.34 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>207<br/> (2 RCTs) </p> <p>21 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 77 fewer wounds healed per 1000</b> </p> <p>(95% CI 167 more to 190 fewer)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants healed ‐ medium term (12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>512 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/> (0.95 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>192<br/> (4 RCTs) </p> <p>89 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 112 more wounds healed per 1000</b> </p> <p>(95% CI 20 fewer to 284 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants healed ‐ long term (over 24 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>678 per 1000<br/> (512 to 902) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.80 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT<sup>ǂ</sup>) </p> <p>66 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Difference: 38 more wounds healed per 1000</b> </p> <p>(95% CI 128 fewer to 262 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants with 1 or more adverse events at 2‐12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>172 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>178 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.75 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>363<br/> (5 RCTs) </p> <p>99 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 6 more adverse events per 1000</b> </p> <p>(95% CI 43 fewer to 72 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk without the intervention is based on the median control group risk across studies. The corresponding risk with the intervention (and the 95% confidence interval for the difference) is based on the overall relative effect (and its 95% confidence interval). </p> <p><sup>ǂ</sup> Same study (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>)<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High:</b> It is very likely that the effect will be close to what was found in the research. </p> <p><b>Moderate:</b> It is likely that the effect will be close to what was found in the research, but there is a possibility that it will be substantially different. </p> <p><b>Low:</b> It is likely that the effect will be substantially different from what was found in the research, but the research provides an indication of what might be expected. </p> <p><b>Very low:</b> The anticipated effect is very uncertain and the research does not provide a reliable indication of what might be expected </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Imprecision (downgraded twice): 66 events, wide CI; assumptions in calculation of HR ‐ no censoring (not downgraded); data extracted from graph (not downgraded) </p> <p><sup>2</sup> Risk of bias (downgraded once): majority of information at high risk of bias. Imprecision (downgraded twice): 21 events and wide CI </p> <p><sup>3</sup> Risk of bias (downgraded once): majority of information at high risk of bias. Imprecision (downgraded once): 89 events, CI consistent with no effect and benefit </p> <p><sup>4</sup> Imprecision (downgraded twice): 66 events, wide CI around absolute effect </p> <p><sup>5</sup> Risk of bias (not downgraded): majority of information at low risk of bias. Imprecision (downgraded twice): 99 events, CI wide around relative effect </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011918-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011918-sec-0023"></div> <section id="CD011918-sec-0024"> <h3 class="title" id="CD011918-sec-0024">Description of the condition</h3> <p>Venous leg ulcers are open skin ulcers (wounds) on the lower leg (from below the ankle up to mid‐calf), that can last weeks, months or even years, and are a consequence of problems in either the superficial or deep veins or both. Damage to the valves or vein blockages result in malfunctioning of the venous system, reducing the efficient return of blood to the heart and increasing the pressure in the leg veins (<a href="./references#CD011918-bbs2-0088" title="GhauriAS , NyamekyeIK . Leg ulceration: the importance of treating the underlying pathophysiology. Phlebology/Venous Forum of the Royal Society of Medicine2010;25(Suppl 1):42‐51. ">Ghauri 2010</a>; <a href="./references#CD011918-bbs2-0140" title="VlajinacH , MarinkovicJ , MaksimovicM , RadakD . Factors related to venous ulceration: a cross‐sectional study. Angiology2014;65(9):824‐30. ">Vlajinac 2014</a>), which, if prolonged may result in venous leg ulcers (VLUs). The precise chain of events that links the high venous pressures with skin breakdown and a chronic wound is not fully understood (<a href="./references#CD011918-bbs2-0080" title="Coleridge SmithPD , ThomasP , ScurrJH , DormandyJA . Causes of venous ulceration: a new hypothesis. British Medical Journal1988;296(6638):1726‐7. ">Coleridge 1988</a>; <a href="./references#CD011918-bbs2-0088" title="GhauriAS , NyamekyeIK . Leg ulceration: the importance of treating the underlying pathophysiology. Phlebology/Venous Forum of the Royal Society of Medicine2010;25(Suppl 1):42‐51. ">Ghauri 2010</a>; <a href="./references#CD011918-bbs2-0138" title="ValenciaIC , FalabellaA , KirsnerRS , EaglsteinWH . Chronic venous insufficiency and venous leg ulceration. Journal of the American Academy of Dermatology2001;44(3):401‐21. ">Valencia 2001</a>). Leg ulcers are frequently associated with venous disease in combination with vascular disease, which impairs arterial blood supply, and such ulcers are said to have a 'mixed aetiology'. </p> <p>Accurate current estimates of leg ulcer prevalence are hard to identify because most surveys do not differentiate between causes of leg ulceration, or do so per limb but not per participant (<a href="./references#CD011918-bbs2-0111" title="MoffattCJ , FranksPJ , DohertyDC , MartinR , BlewettR , RossF . Prevalence of leg ulceration in a London population. QJM: Monthly journal of the Association of Physicians2004;97(7):431‐7. ">Moffatt 2004</a>; <a href="./references#CD011918-bbs2-0131" title="SrinivasaiahN , DugdallH , BarrettS , DrewPJ . A point prevalence survey of wounds in north‐east England. Journal of Wound Care2007;16(10):413‐9. ">Srinivasaiah 2007</a>; <a href="./references#CD011918-bbs2-0141" title="VowdenKR , VowdenP . The prevalence, management and outcome for acute wounds identified in a wound care survey within one English health care district. Journal of Tissue Viability2009;18(1):7‐12. ">Vowden 2009</a>). Estimates of the prevalence of open leg ulceration (any cause) range from 0.4 to 4.8 cases per 1000 (<a href="./references#CD011918-bbs2-0089" title="GrahamID , HarrisonMB , NelsonEA , LorimerK , FisherA . Prevalence of lower‐limb ulceration: a systematic review of prevalence studies. Advances in Skin and Wound Care2003;16(6):305‐16. ">Graham 2003</a>; <a href="./references#CD011918-bbs2-0099" title="JohnsonM . The prevalence of leg ulcers in older people: implications for community nursing. Public Health Nursing1995;12(4):269‐75. ">Johnson 1995;</a><a href="./references#CD011918-bbs2-0142" title="WalkerN , RodgersA , BirchallN , NortonR , MacMahonS . The occurrence of leg ulcers in Auckland: results of a population based study. New Zealand Medical Journal2002;115(1151):159‐62. ">Walker 2002</a>). A recent estimate suggests that venous ulceration has a point prevalence of 0.29 cases per 1000 in the UK, whilst mixed arterial/venous leg ulceration has a point prevalence of 0.11 per 1000 (<a href="./references#CD011918-bbs2-0091" title="HallJ , BuckleyHL , LambKA , StubbsN , SaramagoP , DumvilleJC , et al. Point prevalence of complex wounds in a defined United Kingdom population. Wound Repair and Regeneration2014;22(6):694–700. ">Hall 2014</a>). </p> <p>Venous disease is a chronic condition which is characterised by periods of ulceration (i.e. an open wound) followed by healing and then recurrence, though published contemporary data are lacking (<a href="./references#CD011918-bbs2-0079" title="CallamMJ , HarperDR , DaleJJ , RuckleyCV . Chronic ulcer of the leg: clinical history. British Medical Journal1987;294(6584):1389‐91. ">Callam 1987</a>). An early cross‐sectional study reported that half of current or recent ulcers had been open for up to nine months and that 35% of people with leg ulcers had experienced four or more episodes (<a href="./references#CD011918-bbs2-0079" title="CallamMJ , HarperDR , DaleJJ , RuckleyCV . Chronic ulcer of the leg: clinical history. British Medical Journal1987;294(6584):1389‐91. ">Callam 1987)</a>. This picture was supported by a subsequent cross‐sectional study (<a href="./references#CD011918-bbs2-0114" title="NelzénO , BerqvistD , LindhagenA . Venous and non‐venous leg ulcers: clinical history and appearance in a population study. British Journal of Surgery1994;81(2):182‐7. ">Nelzén 1994</a>). Cohort data from 20,000 people have shown that initial wound area and duration accurately predict healing (<a href="./references#CD011918-bbs2-0108" title="MargolisDJ , Allen‐TaylorL , HoffstadO , BerlinJA . The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair and Regeneration2004;12(2):163‐8. ">Margolis 2004</a>). An ulcer that is smaller than 10 cm² and has a duration shorter than 12 months at first visit has a 29% chance of not healing by the 24th week of care, whilst one larger than 10 cm² and duration longer than 12 months has a 78% chance of not healing by 24 weeks (<a href="./references#CD011918-bbs2-0108" title="MargolisDJ , Allen‐TaylorL , HoffstadO , BerlinJA . The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair and Regeneration2004;12(2):163‐8. ">Margolis 2004</a>). </p> <p>The first line treatment for VLUs is compression therapy in the form of bandages, stockings or mechanical devices (<a href="./references#CD011918-bbs2-0119" title="O'MearaS , CullumN , NelsonEA , DumvilleJC . Compression for venous leg ulcers. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD000265.pub3] ">O'Meara 2012</a>). This application of external pressure around the lower leg assists venous return and reduces venous reflux (<a href="./references#CD011918-bbs2-0086" title="FletcherJ , MoffattC , PartschH , VowdenK , VowdenP . Principles of compression in venous disease: a practitioner’s guide to treatment and prevention of venous leg ulcers. Wounds International 2013; available from www.woundsinternational.com (accessed 15 July 2016). ">Fletcher 2013</a>; <a href="./references#CD011918-bbs2-0119" title="O'MearaS , CullumN , NelsonEA , DumvilleJC . Compression for venous leg ulcers. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD000265.pub3] ">O'Meara 2012</a>). Alongside compression, dressings are almost always applied to open ulcers. The primary rationale for using a dressing is to protect the surface of the ulcer, however other considerations such as absorption of exudate or antimicrobial properties also play a role in treatment selection (<a href="./references#CD011918-bbs2-0121" title="O'MearaS , Al‐KurdiD , OlogunY , OvingtonLG , Martyn St‐JamesM , RichardsonR . Antibiotics and antiseptics for venous leg ulcers. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD003557.pub5] ">O'Meara 2014</a>). Other treatments for VLUs include venous surgery (removal of incompetent superficial veins) (<a href="./references#CD011918-bbs2-0129" title="Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic venous leg ulcers. National clinical guideline 120. August 2010. www.sign.ac.uk/pdf/sign120.pdf (accessed 05 September 2016). ">SIGN 2010</a>); and drugs such as pentoxifylline (<a href="./references#CD011918-bbs2-0100" title="JullAB , ArrollB , ParagV , WatersJ . Pentoxifylline for treating venous leg ulcers. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD001733.pub3] ">Jull 2012</a>). </p> <p>Leg ulcers are associated with considerable cost to patients and to healthcare providers. Two systematic reviews summarised the literature on health‐related quality of life in people with leg ulcers (<a href="./references#CD011918-bbs2-0094" title="HerberOR , SchneppW , RiegerMA . A systematic review on the impact of leg ulceration on patients' quality of life. Health and Quality of Life Outcomes2007;5:44‐55. ">Herber 2007</a>; <a href="./references#CD011918-bbs2-0124" title="PersoonA , HeinenMM , Van derVleutenCJM , DeRoojiMJ , et al. Leg ulcers: a review of their impact on daily life. Journal of Clinical Nursing2004;13(3):341‐54. ">Persoon 2004</a>). Both included qualitative and quantitative evaluations, and reported that presence of leg ulceration was associated with pain, restriction of work and leisure activities, impaired mobility, sleep disturbance, reduced psychological well‐being and social isolation. Ulcers can be painful, malodorous, prone to infection, and may severely affect people's mobility and quality of life (<a href="./references#CD011918-bbs2-0083" title="DumvilleJC , WorthyG , SoaresMO , BlandJM , CullumN , DowsonC , et al. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers. Health Technology Assessment2009;13(55):1‐182. ">Dumville 2009</a>; <a href="./references#CD011918-bbs2-0094" title="HerberOR , SchneppW , RiegerMA . A systematic review on the impact of leg ulceration on patients' quality of life. Health and Quality of Life Outcomes2007;5:44‐55. ">Herber 2007</a>). In severe cases, ulceration can lead to limb amputation, though this is more likely in people who also have arterial insufficiency (<a href="./references#CD011918-bbs2-0083" title="DumvilleJC , WorthyG , SoaresMO , BlandJM , CullumN , DowsonC , et al. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers. Health Technology Assessment2009;13(55):1‐182. ">Dumville 2009</a>; <a href="./references#CD011918-bbs2-0115" title="NelzénO . Prevalence of venous leg ulcer: the importance of the data collection method. Phlebolymphology2008;15(4):143‐50. ">Nelzén 2008</a>; <a href="./references#CD011918-bbs2-0138" title="ValenciaIC , FalabellaA , KirsnerRS , EaglsteinWH . Chronic venous insufficiency and venous leg ulceration. Journal of the American Academy of Dermatology2001;44(3):401‐21. ">Valencia 2001</a>). Recent research suggests that people with complex wounds, including those with VLUs, commonly see complete ulcer healing as the most important outcome to them (<a href="./references#CD011918-bbs2-0107" title="MaddenM . Is research in chronic wound care focusing on the outcomes that matter most to patients?. BSA Annual Conference 2014: Changing Society; 23‐25 April 2014, University of Leeds, UK. 2014:232. ">Madden 2014</a>). </p> <p>The financial cost of treating a person with an open venous leg ulcer in the UK has been estimated at around GBP 1700 per year at 2012 prices. A large part of ulcer treatment cost comprises nursing time (<a href="./references#CD011918-bbs2-0074" title="AshbyRL , GabeR , AliS , AdderleyU , BlandJM , CullumNA , et al. Clinical and cost‐effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial. Lancet2014;383(9920):871‐9. ">Ashby 2014</a>). Another evaluation estimated the average cost of treating a person with a venous leg ulcer in the UK (based on costs for material for dressing changes) as between EUR 814 and EUR 1994 and, in Sweden as between EUR 1332 and EUR 2585 (price year 2002), with higher costs associated with larger and more chronic wounds (<a href="./references#CD011918-bbs2-0125" title="Ragnarson TennvallG , HjelmgrenJ . Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom. Wound Repair and Regeneration2005;13(1):13‐18. ">Ragnarson Tennvall 2005</a>). Data from a German study, which estimated total costs, including those classified as indirect or intangible costs, estimated mean annual costs of treating leg ulcers as EUR 9060 per patient (2006 prices). This figure is higher than other estimates because it includes non‐health service costs to the patient and to society (<a href="./references#CD011918-bbs2-0075" title="AugustinM , BrocattiLK , RustenbachSJ , SchäferI , HerbergerK . Cost‐of‐illness of leg ulcers in the community. International Wound Journal2012;11(3):283‐92. ">Augustin 2012)</a>. A recent Australian cost‐effectiveness study estimated the mean cost per person per week for treating 905 people with a chronic leg or foot ulcer below the knee for 24 weeks as AUD 53.31 (which corresponds to AUD 2772 per year); costs included consultations with healthcare professionals, compression bandaging, other dressings and treatments, and community care services, such as Meals‐on‐Wheels and home help (<a href="./references#CD011918-bbs2-0090" title="GravesN , FinlaysonK , GibbM , O’ReillyM , EdwardsH . Modelling the economic benefits of gold standard care for chronic wounds in a community setting. Wound Practice and Research2014;22(3):163‐8. ">Graves 2014</a>). </p> </section> <section id="CD011918-sec-0025"> <h3 class="title" id="CD011918-sec-0025">Description of the intervention</h3> <p>It has been suggested that one cause of non‐healing in chronic ulcers generally is a prolonged high concentration of proteases in the wound in the later stages of wound healing (<a href="./references#CD011918-bbs2-0092" title="HardingK , ArmstrongDG , BarrettS , KaufmanH , Lázaro‐MartínezJ L , MayerD , et al. International consensus. The role of proteases in wound diagnostics. An expert working group review. 2011. woundchek.com/uploads/downloads/consensus_documents/Role‐of‐proteases‐in‐wound‐diagnostics‐International.pdf. London, (accessed 15 July 2016). ">Harding 2011</a>; <a href="./references#CD011918-bbs2-0093" title="HartJ , SilcockD , GunnigleS , CullenB , LightND , WattPW . The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. The International Journal of Biochemistry &amp; Cell Biology2002;34(12):1557–70. ">Hart 2002</a>; <a href="./references#CD011918-bbs2-0122" title="PalolahtiM , LauharantaJ , StephensRW , KuuselaP , VaheriA . Proteolytic activity in leg ulcer exudate. Experimental Dermatology1993;2(1):29‐37. ">Palolahti 1993</a>). 'Protease‐modulating' matrix (protease‐inhibiting) treatments are designed to reduce these levels of proteases. </p> <p>Proteases are enzymes that break down proteins into peptides and amino acids. The principal proteases involved in wound healing are the matrix metalloproteinases and the serine proteases that break down extracellular matrix and connective tissue proteins such as collagen and elastin (<a href="./references#CD011918-bbs2-0102" title="LadwigGP , RobsonMC , LiuR , KuhnMA , MuirDF , SchultzGS . Ratios of activated matrix metalloproteinase‐9 to tissue inhibitor of matrix metalloproteinase‐1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair and Regeneration2002;10(1):26‐37. ">Ladwig 2002</a>; <a href="./references#CD011918-bbs2-0118" title="NwomehBC , LiangHX , CohenIK , YagerDR . MMP‐8 is the predominant collagenase in healing wounds and nonhealing ulcers. Journal of Surgical Research1999;81(2):189‐95. ">Nwomeh 1999</a>; <a href="./references#CD011918-bbs2-0139" title="VelnarT , BaileyT , SmrkoljV . The wound healing process: an overview of the cellular and molecular mechanisms. Journal of International Medical Research2009;37(5):1528‐42. ">Velnar 2009</a>). </p> <p>Proteases are active in all of the phases of wound healing (haemostasis, inflammation, proliferation and remodelling) and are therefore thought to have a number of roles in the normal wound healing process (<a href="./references#CD011918-bbs2-0137" title="TrengoveNJ , StaceyMC , MacAuleyS , BennettN , GibsonJ , BurslemF , et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair and Regeneration1999;7(6):442‐52. ">Trengove 1999</a>; <a href="./references#CD011918-bbs2-0139" title="VelnarT , BaileyT , SmrkoljV . The wound healing process: an overview of the cellular and molecular mechanisms. Journal of International Medical Research2009;37(5):1528‐42. ">Velnar 2009</a>). It is thought that there is a burst of protease activity at the start of acute wound healing, and that in normally‐healing wounds, the activity peaks in the first few days and then declines to very low levels by one week, as healing progresses (<a href="./references#CD011918-bbs2-0092" title="HardingK , ArmstrongDG , BarrettS , KaufmanH , Lázaro‐MartínezJ L , MayerD , et al. International consensus. The role of proteases in wound diagnostics. An expert working group review. 2011. woundchek.com/uploads/downloads/consensus_documents/Role‐of‐proteases‐in‐wound‐diagnostics‐International.pdf. London, (accessed 15 July 2016). ">Harding 2011</a>; <a href="./references#CD011918-bbs2-0117" title="NwomehBC , LiangHX , DiegelmannRF , CohenIK , YagerDR . Dynamics of the matrix metalloproteinases MMP‐1 and MMP‐8 in acute open human dermal wounds. Wound Repair and Regeneration1998;6(2):127‐34. ">Nwomeh 1998</a>). </p> <p>In non‐healing wounds, however, it is thought that complex inflammatory mechanisms may result in proteases reaching higher levels and persisting for longer than in normally‐healing wounds (<a href="./references#CD011918-bbs2-0137" title="TrengoveNJ , StaceyMC , MacAuleyS , BennettN , GibsonJ , BurslemF , et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair and Regeneration1999;7(6):442‐52. ">Trengove 1999</a>). This persistent proteolytic activity is thought to damage newly formed tissue and to degrade growth factors, leading to non‐healing wounds (<a href="./references#CD011918-bbs2-0081" title="CullenB , SmithR , McCullochE , SilcockD , MorrissonL . Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair and Regeneration2002;10(1):16‐25. ">Cullen 2002</a>; <a href="./references#CD011918-bbs2-0092" title="HardingK , ArmstrongDG , BarrettS , KaufmanH , Lázaro‐MartínezJ L , MayerD , et al. International consensus. The role of proteases in wound diagnostics. An expert working group review. 2011. woundchek.com/uploads/downloads/consensus_documents/Role‐of‐proteases‐in‐wound‐diagnostics‐International.pdf. London, (accessed 15 July 2016). ">Harding 2011</a>; <a href="./references#CD011918-bbs2-0144" title="WlaschekM , PeusD , AchterbergV , Meyer‐IngoldW , Scharffetter‐KochanekK . Protease inhibitors protect growth factor activity in chronic wounds. British Journal of Dermatology1997;137(4):646‐66. ">Wlaschek 1997</a>; <a href="./references#CD011918-bbs2-0146" title="YagerDR , ChenSM , WardSI , OlutoyeOO , DiegelmannRF , CohenIK . Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair and Regeneration1997;5(1):23‐32. ">Yager 1997</a>). Limited evidence suggests correlations between elevated levels of matrix metalloproteinases and delayed healing in people with pressure ulcers (<a href="./references#CD011918-bbs2-0102" title="LadwigGP , RobsonMC , LiuR , KuhnMA , MuirDF , SchultzGS . Ratios of activated matrix metalloproteinase‐9 to tissue inhibitor of matrix metalloproteinase‐1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair and Regeneration2002;10(1):26‐37. ">Ladwig 2002</a>), or in foot ulcers in people with diabetes (<a href="./references#CD011918-bbs2-0105" title="LiuY , MinD , BoltonT , NubeV , TwiggSM , YueDK , et al. Increased matrix metalloproteinase‐9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care2009;32(1):117‐9. ">Liu 2009</a>), as well as in people with VLUs (<a href="./references#CD011918-bbs2-0112" title="MwauraB , MahendranB , HynesN , DefreitasD , AvalosG , AdegbolaT , et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase‐2, tissue inhibitor of matrix metalloproteinase‐2 and PDGF‐AA on the chronicity of venous leg ulcers. European Journal of Vascular and Endovascular Surgery2006;31(3):306‐10. ">Mwaura 2006</a>; <a href="./references#CD011918-bbs2-0053" title="SerraR , BuffoneG , FalconeD , MolinariV , ScaramuzzinoM , GallelliL , et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases‐9 and neutrophil gelatinase‐associated lipocalin. Wound Repair and Regeneration2013;21(3):395‐402. [DOI: 10.1111/wrr.12035] ">Serra 2013</a>). </p> <p>For VLUs in particular, studies of protease levels in wound fluid suggest that there are significantly higher levels of proteases in ulcer tissue compared with healthy tissue, and that these levels decrease following compression treatment in wounds that heal (<a href="./references#CD011918-bbs2-0077" title="BeidlerSK , DouilletCD , BerndtDF , KeagyBA , RichPB , MarstonWA . Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair and Regeneration2008;16(5):642‐8. ">Beidler 2008</a>). Furthermore, it has been suggested that bacteria present in infected wounds may also produce proteases and these may work synergistically with host proteases to direct tissue degradation (<a href="./references#CD011918-bbs2-0109" title="McCartySM , CochraneCA , CleggPD , PercivalSL . The role of endogenous and exogenous enzymes in chronic wounds: A focus on the implications of aberrant levels of both host and bacterial proteases in wound healing. Wound Repair and Regeneration2012;20(2):125–36. ">McCarty 2012</a>). </p> <p>It is logical therefore to postulate that interventions that reduce protease levels may promote wound healing where there are high levels of protease activity. </p> <p>There is a lack of clarity in the literature as to what constitutes a protease‐modulating matrix (PMM) treatment. For example, some authors have categorised super absorbant dressings as "protease‐modulating" (<a href="./references#CD011918-bbs2-0145" title="MA Healthcare. Wound Care Handbook. www.woundcarehandbook.com/ (accessed 10 October 2016). ">Wound Care Handbook 2016</a>)), whilst other texts do not describe them as such. For the purposes of this review we defined a PMM treatment as a product that had a purposeful intent of reducing proteases. With important clinical input, we produced a taxonomy for defining PMM treatments to be those specifically marketed as having protease‐modulating activity, with this being a key feature of the product; and where no commercial product was named, the study reported a specific intent of modulating proteases. Common PMM treatments are described below. Products are listed by their generic names and, when possible, with examples of corresponding trade names and manufacturers. Both dressings and ointments are available; some dressings have silver ions incorporated, which are intended to reduce wound pathogens. </p> <p>Types of PMM treatment include the following (<a href="./references#CD011918-bbs2-0078" title="Joint Formulary Committee. British National Formulary (BNF). www.evidence.nhs.uk/formulary/bnf/current/a5‐wound‐management‐products‐and‐elasticated‐garments (accessed 14 December 2016). ">BNF 2016</a>; <a href="./references#CD011918-bbs2-0145" title="MA Healthcare. Wound Care Handbook. www.woundcarehandbook.com/ (accessed 10 October 2016). ">Wound Care Handbook 2016</a><a href="./references#CD011918-bbs2-0147" title="YoungT . Using a protease test to inform wound care treatment decisions. Wounds UK2012;8(4):74‐80. ">Young 2012</a>): </p> <p> <ul id="CD011918-list-0001"> <li> <p>starch based ointment: Cadesorb® (Smith &amp; Nephew)</p> </li> <li> <p>collagen matrix: Suprasorb® C (Activa); Catrix® (Cranage)</p> </li> <li> <p>collagen and oxidised regenerated cellulose matrix dressing: Promogran® (Systagenix)</p> </li> <li> <p>collagen, silver and oxidised regenerated cellulose matrix dressing: Promogran® Prisma® Matrix (Systagenix) </p> </li> <li> <p>cellulose acetate matrix, impregnated with polyhydrated ionogens ointment in polyethylene glycol basis dressing: Tegaderm® Matrix (3M) </p> </li> <li> <p>adherent polymer matrix dressing containing nano‐oligosaccharide factor (NOSF), with polyurethane foam film backing: UrgoStart® (Urgo) </p> </li> <li> <p>non‐adherent wound contact dressing containing NOSF: UrgoStart® Contact (Urgo)</p> </li> <li> <p>cellulose and polymer in a polypropylene sachet: DryMax® Extra (Aspen Medical).</p> </li> </ul> </p> <p>Costs range from GBP 2.96 to GBP 9.18 (median GBP 4.75) (<a href="./references#CD011918-bbs2-0078" title="Joint Formulary Committee. British National Formulary (BNF). www.evidence.nhs.uk/formulary/bnf/current/a5‐wound‐management‐products‐and‐elasticated‐garments (accessed 14 December 2016). ">BNF 2016</a>). These costs are higher than for the advanced wound dressings typically used for leg ulcers including alginate dressings (median GBP 0.82) and hydrogels (median GBP 1.92) (<a href="./references#CD011918-bbs2-0078" title="Joint Formulary Committee. British National Formulary (BNF). www.evidence.nhs.uk/formulary/bnf/current/a5‐wound‐management‐products‐and‐elasticated‐garments (accessed 14 December 2016). ">BNF 2016</a>). Annual prescribing volumes (as categorised by the BNF) in England for the period October 2008 to September 2009 are available, and state that 6.3% (about 0.2 million items) of advanced wound dressings were protease modulating (<a href="./references#CD011918-bbs2-0110" title="MeReCpublications . Evidence‐based prescribing of advanced wound dressings for chronic wounds in primary care. MeReC Bulletin2010;21(1). ">MeReC 2010</a>). </p> </section> <section id="CD011918-sec-0026"> <h3 class="title" id="CD011918-sec-0026">How the intervention might work</h3> <p>PMM treatments are used with the aim of increasing wound healing via a reduction in the levels of proteases. The principle of PMM treatments is both to absorb and bind excess proteases from wound fluids, thereby reducing levels of protease at the wound bed (<a href="./references#CD011918-bbs2-0081" title="CullenB , SmithR , McCullochE , SilcockD , MorrissonL . Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair and Regeneration2002;10(1):16‐25. ">Cullen 2002</a>).These treatments do not, however, appear to affect the expression of proteases on a cellular level (<a href="./references#CD011918-bbs2-0106" title="LobmannR , ZemlinC , MotzkauM , ResckeK , LehnertH . Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.. Journal of Diabetes and its Complications2006;20(5):329‐35. ">Lobmann 2006</a>). Treatments can target specific proteases or can be more broad spectrum, designed to inhibit the activity of more than one protease. It is likely that in trials, PMM treatments have been given to people who have already had other treatments (particularly compression). However, this review is also interested in protease‐modulating treatment as first line therapy. Point‐of‐care tests are currently being marketed that are intended to identify wounds with persistently high protease levels in order to target treatment appropriately (<a href="./references#CD011918-bbs2-0116" title="NormanG , WestbyMJ , StubbsN , DumvilleJC , CullumN . A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD011753] ">Norman 2016</a>). </p> </section> <section id="CD011918-sec-0027"> <h3 class="title" id="CD011918-sec-0027">Why it is important to do this review</h3> <p>VLUs are a relatively common, complex type of wound that have a negative impact on people's lives and incur high costs for health services. Leg ulcers are painful, malodorous, prone to infection, and may severely affect patients' mobility and quality of life. In severe cases VLUs may lead to limb amputation. There are a number of treatments for VLUs available and in use, especially compression treatment. However many people experience ulcers that have been open for several months or that recur, or both. Evidence from one large randomised controlled trial (RCT) (<a href="./references#CD011918-bbs2-0098" title="IglesiasC , NelsonEA , CullumNA , TorgersonDJ . VenUS 1: a randomised controlled trial of two types of bandage for treating venous leg ulcers. Health Technology Assessment2004;8(29). ">Iglesias 2004</a>) in two types of compression treatment showed that healing occurred in 55% and 68% after 24 weeks' treatment, so there is still scope for further improvement from other treatments. PMM treatments are designed to improve the healing of these hard‐to‐heal venous ulcers. </p> <p>We have been unable to identify an existing systematic review of RCTs investigating the effectiveness of these treatments for VLUs, although PMM treatments are included as comparators in one Cochrane review (<a href="./references#CD011918-bbs2-0120" title="O'MearaS , Martyn‐St JamesM . Foam dressings for venous leg ulcers. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD009907.pub2] ">O'Meara 2013</a>); we concluded that an up‐to‐date and transparent evidence summary was required on the use of PMM treatments for VLUs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011918-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011918-sec-0028"></div> <p>To determine the effects of protease‐modulating matrix treatments on the healing of venous leg ulcers, in people managed in any care setting. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011918-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011918-sec-0029"></div> <section id="CD011918-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011918-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included published and unpublished RCTs, including cluster RCTs (for which the participant with multiple ulcers was the 'cluster'), irrespective of language of report. Crossover trials would only be included if they reported outcome data at end of the first treatment period and prior to crossover. We excluded studies using quasi‐random methods of allocation (such as alternation). </p> </section> <section id="CD011918-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies recruiting people with a VLU, managed in any care setting. Studies recruiting people described as having VLU were eligible for inclusion. The method of diagnosis of venous ulceration was expected to vary, so we accepted definitions as used in the studies. </p> <p>We included trials recruiting people with VLUs, alongside people with other types of wounds (e.g. arterial ulcers, pressure ulcers, diabetic foot ulcers), provided the results for people with venous ulcers were presented separately, or if the majority of participants (at least 75% in each arm at randomisation) had leg ulcers of venous aetiology. </p> <p>We included participants at any stage in their treatment pathway, for example, participants with or without hard‐to‐heal ulcers; and participants selected on the basis of high protease levels, or unselected participants, or people without protease measurements. We also included participants irrespective of infection status at baseline: any available data on these were recorded. </p> </section> <section id="CD011918-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The primary intervention of interest was a PMM treatment of any type, including dressings and topical treatments. We defined PMM treatments as those specifically marketed as having protease‐modulating activity, with this being a key feature of the product and where no commercial product was named, the study reported a specific intent of modulating proteases. Dressings could be collagen alone, collagen plus oxidised regenerated cellulose (ORC), collagen plus ORC plus other treatments (such as silver, i.e. a combined role), etc. We included any RCTs in which the PMM treatment was the only systematic difference between intervention groups. </p> <p>We anticipated that likely initial comparisons would include (i) any PMM treatment versus any conventional dressing, (ii) any PMM treatment versus treatment as usual, and (iii) comparisons of different PMM treatments. We planned to treat PMM interventions as a class, combining all types in the meta‐analysis. </p> <p>For first line PMM treatment, the timing of the intervention was expected to be an important feature; we also planned to include studies that compared different application timings or durations, as long as the difference in timing was the only systematic difference between groups. </p> <p>Studies in which both groups of participants received compression (adjunct) would be initially meta‐analysed with those that did not give compression to either group, and later examined in subgroup analyses if there was heterogeneity: compression is known to be an effective treatment in terms of reducing time to ulcer healing (<a href="./references#CD011918-bbs2-0119" title="O'MearaS , CullumN , NelsonEA , DumvilleJC . Compression for venous leg ulcers. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD000265.pub3] ">O'Meara 2012</a>). We would not include studies in which the provision of compression varied between study groups because the PMM treatment would not be the only systematic difference between groups. </p> <p>We described the polymeric material and reported generic names where possible, and also provided trade names and manufacturers where these were available. </p> <p>We excluded from this review evaluations of 'test‐and‐treat' approaches that initiate PMM treatments on the basis of formal measurement of protease levels. These trials are reported in the concurrent Cochrane review, "A test and treat policy for elevated wound protease activity for healing in venous leg ulcers" (<a href="./references#CD011918-bbs2-0116" title="NormanG , WestbyMJ , StubbsN , DumvilleJC , CullumN . A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD011753] ">Norman 2016</a>). </p> </section> <section id="CD011918-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We list primary and secondary outcomes below. If a study was otherwise eligible (i.e. correct study design, population and intervention/comparator) but did not report a listed outcome then we contacted the study authors where possible to establish whether an outcome of interest here was measured but not reported. </p> <p>It is important to take time into account in the reporting of outcome measures. Where possible, we used or calculated time‐to‐event data. Otherwise, we categorised outcomes data as follows: </p> <p> <ul id="CD011918-list-0002"> <li> <p>one week or less to 8 weeks = short‐term outcome;</p> </li> <li> <p>more than 8 weeks to 24 weeks = medium‐term outcome; and</p> </li> <li> <p>more than 24 weeks = long‐term outcome.</p> </li> </ul> </p> <p>If results were given at more than one time point in a study, we reported outcome measures at the latest time point available (assumed to be length of follow‐up if not specified) or the time point specified in the study report's Methods section as being of primary interest (if this was different from latest time point available). This avoided statistical issues inherent in the use of multiple time points. 'Follow‐up' is defined as the time from randomisation to outcome measurement. The review authors' judgement was used as to whether statistical pooling within the above time categories was appropriate. </p> <p>We analysed the data separately for the three durations for the complete healing outcome, but combined durations for adverse events (reasoning that local adverse events would probably occur fairly quickly). </p> <section id="CD011918-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD011918-sec-0036"> <h6 class="title">1. Complete ulcer healing</h6> <p>The primary outcome for the review was complete ulcer healing. We regarded the following as the most relevant and rigorous measures of this outcome: </p> <p> <ul id="CD011918-list-0003"> <li> <p>time to complete ulcer healing (correctly analysed using survival, time‐to‐event approaches, ideally with adjustment for relevant covariates such as baseline size); </p> </li> <li> <p>the proportion of people with ulcers completely healed.</p> </li> </ul> </p> <p>Where both of these outcomes were reported we planned to present all data in a summary outcome table for reference, but to regard time to healing as having primacy. When time was analysed as a continuous measure, but it was not clear whether all ulcers healed, we planned to document the use of the outcome in the study, but not to extract, summarise or use the data in any meta‐analysis. </p> </section> <section id="CD011918-sec-0037"> <h6 class="title">2. Adverse events</h6> <p>Events defined, and grouped together, as 'adverse events' by studies were reported where a clear methodology for the collection of adverse event data was provided. This methodology should have made it clear whether (i) events were reported at the participant level; or (ii) if multiple events per person were reported, that an appropriate adjustment was made for data clustering. Where available, we planned to extract data on all serious adverse events and all non‐serious adverse events. We anticipated that adverse events for PMM treatments would be likely to be similar to those for conventional treatments (e.g. deterioration, infection, maceration, pruritis). </p> </section> </section> <section id="CD011918-sec-0038"> <h5 class="title">Secondary outcomes</h5> <section id="CD011918-sec-0039"> <h6 class="title">3. Health‐related quality of life</h6> <p>We included health‐related quality of life where it was reported using a validated scale such as the SF‐36 or EQ‐5D or a validated disease‐specific questionnaire such as the Cardiff Wound Impact Schedule. Ideally, reported data would be adjusted for the baseline score. We did not include <i>ad hoc</i> measures of quality of life that were unlikely to be validated and would not be common to multiple trials. </p> </section> <section id="CD011918-sec-0040"> <h6 class="title">4. Pain (including pain at dressing change)</h6> <p>Mean pain scores were included only where they were reported either as presence or absence of pain, or as a continuous outcome using a validated scale such as a visual analogue scale (VAS). </p> </section> <section id="CD011918-sec-0041"> <h6 class="title">5. Infection</h6> <p>We noted whether wounds were infected at baseline and investigated, where possible, any reduction in infection (efficacy) or incidence of infection (adverse events), or both. We did not consider measurement of bacterial counts. </p> </section> <section id="CD011918-sec-0042"> <h6 class="title">6. Change in ulcer size</h6> <p>If there were no ulcer healing data for a particular comparison, we planned to consider using data on the change (and percentage change) in ulcer size, with adjustment for baseline size (contacting study authors to request adjusted means when not presented). Where change in ulcer size was reported without adjustment for baseline size, use of the outcome in the study would have been documented, but data would not have been extracted, summarised or used in any meta‐analysis. </p> </section> <section id="CD011918-sec-0043"> <h6 class="title">7. Resource use</h6> <p>Mean or median summaries of resource use were reported (including measurements of resource use such as number of dressing changes, nurse visits, length of hospital stay and re‐operation/intervention). </p> </section> <section id="CD011918-sec-0044"> <h6 class="title">8. Costs</h6> <p>Mean costs associated with resource use (as described above) and estimates of cost‐effectiveness.</p> </section> </section> </section> </section> <section id="CD011918-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011918-sec-0046"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to identify relevant RCTs:</p> <p> <ul id="CD011918-list-0004"> <li> <p>Cochrane Wounds Specialised Register (searched 19 September 2016);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; <i>The Cochrane Library</i> 2016, Issue 8); </p> </li> <li> <p>Ovid MEDLINE (1946 to 19 September 2016);</p> </li> <li> <p>Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations) (searched 19 September 2016);</p> </li> <li> <p>Ovid Embase (1974 to 16 September 2016);</p> </li> <li> <p>EBSCO CINAHL Plus (1937 to 16 September 2016).</p> </li> </ul> </p> <p>The search strategies for CENTRAL, Ovid MEDLINE, Ovid Embase and EBSCO CINAHL Plus can be found in <a href="./appendices#CD011918-sec-0111">Appendix 1</a>. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision) (<a href="./references#CD011918-bbs2-0103" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). We combined the Embase search with the Ovid Embase randomised trials filter terms developed by the UK Cochrane Centre (<a href="./references#CD011918-bbs2-0103" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). We combined the CINAHL search with the randomised trials filter terms developed by the Scottish Intercollegiate Guidelines Network (<a href="./references#CD011918-bbs2-0130" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. www.sign.ac.uk/methodology/filters.html (accessed 8 July 2016). ">SIGN 2015</a>). There were no restrictions with respect to language, date of publication or study setting. </p> <p>We also searched the following clinical trials registries:</p> <p> <ul id="CD011918-list-0005"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a>) </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>). </p> </li> </ul> </p> </section> <section id="CD011918-sec-0047"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included studies as well as relevant systematic reviews, meta‐analyses, and health‐technology assessment reports. </p> <p>We contacted corresponding study authors for further information (where necessary) and three responded (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>). </p> <p>We also checked the results of the search conducted for a related review (<a href="./references#CD011918-bbs2-0116" title="NormanG , WestbyMJ , StubbsN , DumvilleJC , CullumN . A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD011753] ">Norman 2016</a>), and the PRISMA diagram is given for the combined records (<a href="./references#CD011918-bbs2-0104" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA Statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100. ">Liberati 2009</a>; <a href="#CD011918-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011918-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011918-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> </section> <section id="CD011918-sec-0048"> <h3 class="title" id="CD011918-sec-0048">Data collection and analysis</h3> <section id="CD011918-sec-0049"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed the search results (titles and abstracts) against the eligibility criteria. After this initial assessment, we obtained full‐text copies of all studies considered to be potentially eligible. Two review authors independently checked the full papers for eligibility; we resolved disagreements by discussion and, where required, with the input of a third review author. Where required and possible, we contacted study authors where the eligibility of a study was unclear. We recorded all reasons for exclusion of studies for which we had obtained full copies. We completed a PRISMA flowchart to summarise this process (<a href="./references#CD011918-bbs2-0104" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA Statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100. ">Liberati 2009</a>; <a href="#CD011918-fig-0001">Figure 1</a>). </p> <p>Where studies were reported in multiple publications/reports we obtained all of them. Whilst we only included the study once in the review, we extracted data from all reports to ensure that we obtained maximal relevant data. </p> </section> <section id="CD011918-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently and resolved disagreements by discussion, drawing on a third review author where required. Where data were missing from reports, we attempted to contact the study authors to obtain this information. </p> <p>We planned that, where a study with more than two randomised interventions was included, we would only extract data from groups that met the eligibility criteria and would simply note any additional arms. However, there were no studies in which this occurred. </p> <p>We extracted the following data where possible by treatment group for the pre‐specified interventions and outcomes in this review. We collected outcome data for relevant time points as described in <a href="#CD011918-sec-0034">Types of outcome measures</a>: </p> <p> <ul id="CD011918-list-0006"> <li> <p>Country in which study conducted</p> </li> <li> <p>Unit of randomisation: cluster, participant; wounds (for split‐site or split‐body study); foot/leg </p> </li> <li> <p>Trial design e.g. parallel; cluster; ulcer randomisation; crossover trials with first period results </p> </li> <li> <p>Publication status of study</p> </li> <li> <p>Source of funding</p> </li> <li> <p>Care setting</p> </li> <li> <p>Number of participants randomised to each trial arm and a note taken of additional excluded intervention arms, with numbers randomised </p> </li> <li> <p>Inclusion and exclusion criteria (including selection on basis of protease levels)</p> </li> <li> <p>Population baseline characteristics:</p> <ul id="CD011918-list-0007"> <li> <p>age</p> </li> <li> <p>sex</p> </li> <li> <p>duration of venous leg ulcer</p> </li> <li> <p>ulcer area at baseline</p> </li> <li> <p>proportion of participants with infected ulcers at baseline</p> </li> <li> <p>protease levels at baseline</p> </li> </ul> </li> <li> <p>Treatment received by each group:</p> <ul id="CD011918-list-0008"> <li> <p>details of treatment regimen, including polymer type/structure</p> </li> <li> <p>mode of delivery of treatment (e.g. dressing or topical treatment)</p> </li> <li> <p>number of applications of treatment</p> </li> <li> <p>timing of treatment (initiation relative to time of randomisation)</p> </li> <li> <p>duration of treatment and duration of follow‐up</p> </li> <li> <p>details of any co‐interventions, especially compression interventions</p> </li> <li> <p>details of any background treatment and any subsequent treatment post randomisation</p> </li> </ul> </li> <li> <p>Prior treatment (type, if any, or treatment naive)</p> </li> <li> <p>Primary and secondary outcome(s) (with definitions)</p> </li> <li> <p>Unit of analysis</p> </li> <li> <p>Details of analysis</p> <ul id="CD011918-list-0009"> <li> <p>e.g. time‐to‐event analysis method such as Cox proportional hazards; regression adjusted for which list of covariates </p> </li> <li> <p>where mean or median time to healing without survival analysis has been conducted (i.e. time to healing treated as a continuous measure without censoring and whether this was done as all ulcers healed) </p> </li> </ul> </li> <li> <p>Outcome data for primary and secondary outcomes (by group)</p> </li> <li> <p>Withdrawals per treatment group with numbers and reasons.</p> </li> </ul> </p> </section> <section id="CD011918-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed included studies using the Cochrane tool for assessing risk of bias (<a href="./references#CD011918-bbs2-0096" title="HigginsJP , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). This tool addresses six specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting, and other issues (<a href="./appendices#CD011918-sec-0112">Appendix 2</a>). In this review, we also recorded issues with the unit of analysis, for example where a cluster trial had been undertaken but analysed at the individual level in the study report (<a href="./appendices#CD011918-sec-0137">Appendix 3</a>). Additionally, we recorded in the notes the comparability of participant characteristics at baseline across the two groups, especially the values of continuous outcomes at baseline, and whether an adjusted analysis was conducted. We used these data to help inform decisions on the risk of selection bias. </p> <p>We assessed blinding and completeness of outcome data for each of the review outcomes separately. We note that, since judgement is exercised in determining when ulcer healing has actually occurred, the outcome of healing can be at high risk of detection bias when outcome assessment is not masked to treatment allocation. </p> <p>We presented our assessment of risk of bias using two 'Risk of bias' summary figures; one of which shows a cross‐tabulation of each trial by all of the risk of bias items (<a href="#CD011918-fig-0002">Figure 2</a>), and a second which is a summary of bias for each item across all studies (<a href="#CD011918-fig-0003">Figure 3</a>). We classed studies with an assessment of high risk of bias for the randomisation sequence or the allocation concealment domain or the blinded outcome assessment domain or incomplete outcome data (or combinations thereof) as being at overall high risk of bias (for the specified outcome for that study), and noted if there were two or more domains contributing to the overall risk of bias. </p> <div class="figure" id="CD011918-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011918-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD011918-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011918-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <p>If there were any trials using cluster randomisation, we planned to consider the risk of bias in terms of recruitment bias, baseline imbalance, loss of clusters, incorrect analysis, and comparability with individually randomised trials (<a href="./references#CD011918-bbs2-0097" title="HigginsJP , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>) (<a href="./appendices#CD011918-sec-0137">Appendix 3</a>). However, no studies had cluster randomisation. </p> </section> <section id="CD011918-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes the risk ratio (RR) was calculated with its 95% confidence interval (CI). Where there were no events in either arm, the study was included in the analysis (but did not contribute to the summary estimate). Where the event risk was less than 1% in any one arm, we calculated a Peto Odds Ratio (OR) with its 95% CI. </p> <p>For continuous outcome data we used the mean difference (MD) with its 95% CI, if all trials used the same or similar (magnitude) assessment scale. If trials used different magnitude assessment scales, we would have used the standardised mean difference (SMD) with 95% CIs. </p> <p>For time‐to‐complete ulcer healing, we reported data as hazard ratios (HR) (with their 95% CI), in accordance with the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011918-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). If studies reporting time‐to‐event data (e.g. time to healing) did not report a hazard ratio, we estimated this using other reported data, such as the numbers of events, with application of available statistical methods (<a href="./references#CD011918-bbs2-0123" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(30):2815‐34. ">Parmar 1998</a>; <a href="./references#CD011918-bbs2-0136" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(16). [DOI: 10.1186/1745‐6215‐8‐16] ">Tierney 2007</a>; <a href="./references#CD011918-bbs2-0143" title="WangY , ZengT . Response to: Practical methods for incorporating summary time‐to‐event data into meta‐analysis [addendum to Tierney 2007]. Trials2013;14(391). [DOI: 10.1186/1745‐6215‐14‐391] ">Wang 2013</a>). In the absence of these measures, if there had been any studies in which all ulcers healed, we would have considered the mean or median time to healing without survival analysis as a valid outcome (i.e. if the trial authors regarded time to healing as a continuous measure because there was no censoring). However, no studies met these criteria. </p> </section> <section id="CD011918-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to treat the participant as the unit of analysis if studies randomised at the participant level, measured outcomes at the ulcer level (e.g. ulcer healing), and the number of ulcers assessed appeared to be equal to the number of participants (e.g. one wound per person). However, this issue did not arise for any studies. </p> <p>We anticipated a possible unit‐of‐analysis issue if individual participants with multiple ulcers were randomised, the allocated treatment was used on multiple ulcers per participant (or perhaps only for some participants) and then data were presented and analysed by ulcer not person. This is a type of clustered data, such that the participant is the 'cluster', and presents a unit of analysis error which inflates precision. If there had been studies that contained some or all clustered data we would have reported this alongside information on whether data had been (incorrectly) treated as independent. We would have recorded this as part of the 'Risk of bias' assessment. We would not have undertaken further calculation to adjust for clustering. However, no studies of this type were included. </p> <p>We also noted when randomisation used a split‐site or split‐body design, and assessed whether the correct paired analysis had been undertaken in the study. Again, we recorded issues in the 'Risk of bias' section. If an incorrect analysis had been undertaken and the required data had been available from the study report or the study authors, we would have approximated a correct analysis (<a href="./references#CD011918-bbs2-0073" title="AltmanDG , MachinD , BryantTN , GardnerMJ . Statistics with confidence. 2nd Edition. London: BMJ, 2000. ">Altman 2000</a>; <a href="./references#CD011918-bbs2-0084" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). However, this was not available for the included study with a split‐site design. If the majority of the evidence had had incorrect analyses, we would have considered conducting separate meta‐analyses for incorrectly analysed data and adjusting the 'Risk of bias' assessment accordingly. However, only one study had a split‐site design. We included this study in the meta‐analysis, accepting that its contribution would be reduced. </p> </section> <section id="CD011918-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>It is common to have data missing from trial reports. Excluding participants post‐randomisation, or ignoring those participants who withdraw from the trial or are lost to follow‐up, compromises the randomisation and potentially introduces bias into the trial. Where there were missing data that the review authors thought should be included in the analyses, the relevant study authors were contacted to request whether these data were available and to determine reasons for 'missingness'; however, we noted it was likely that data would often be missing due to loss to follow‐up. </p> <p>Where data remained missing for the primary outcome of proportion healed, we assumed participants did not have the outcome (i.e. they were considered in the denominator but not the numerator). We conducted a sensitivity analysis using an alternative imputation approach (available case analysis) to examine this assumption. </p> <p>For continuous variables, for example, quality of life, we presented available data from the study reports/study authors and did not impute missing data. </p> <p>For adverse events and all secondary dichotomous outcomes we used an available case analysis, where possible, for all studies; and failing that, used whatever the study authors reported. Where measures of variance were missing, we calculated these wherever possible (<a href="./references#CD011918-bbs2-0096" title="HigginsJP , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). If these data were not available and calculation was not possible, we would have contacted the study authors, and if this was unsuccessful, we would have excluded the study from any relevant meta‐analyses that were conducted. However, this issue did not arise. </p> </section> <section id="CD011918-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>Assessment of heterogeneity comprised initial assessment of clinical and methodological heterogeneity and the appropriateness of combining study results: that is the degree to which the included studies varied in terms of participant, intervention, outcome and characteristics such as length of follow‐up. This assessment of clinical and methodological heterogeneity was supplemented by information regarding statistical heterogeneity of the results — assessed using the Chi² test (we considered a significance level of P &lt; 0.10 to indicate statistically significant heterogeneity) in conjunction with the I² measure (<a href="./references#CD011918-bbs2-0095" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). I² examines the percentage of total variation across RCTs that is due to heterogeneity rather than chance (<a href="./references#CD011918-bbs2-0095" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). In general I² values of 25%, or less, may mean a low level of heterogeneity (<a href="./references#CD011918-bbs2-0095" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), and values of 75%, or more, indicate very high heterogeneity (<a href="./references#CD011918-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We also examined the variability of the point estimates and the overlap of the confidence intervals, when I² values were less than 50%. Where there was possible heterogeneity we explored this further: see <a href="#CD011918-sec-0057">Data synthesis</a>. </p> </section> <section id="CD011918-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. Publication bias, an across‐studies reporting bias, is one of a number of possible causes of 'small study effects', that is, a tendency for estimates of the intervention effect to be more beneficial in smaller RCTs. Funnel plots allow a visual assessment of whether small study effects may be present in a meta‐analysis. A funnel plot is a simple scatter plot of the effect estimates from individual RCTs against some measure of trial size or precision (<a href="./references#CD011918-bbs2-0132" title="SterneJA , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). If we had had meta‐analyses with 10 RCTs or more, we would have presented funnel plots using Cochrane's Review Manager (RevMan) 5 software (<a href="./references#CD011918-bbs2-0126" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). However, we did not have sufficient studies for this. </p> <p>We also considered the publication status of the studies and their funding.</p> </section> <section id="CD011918-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We reviewed details of included studies at the level of comparison between intervention and comparator, stratified by outcomes by time point. </p> <p>We considered clinical and methodological heterogeneity (based on the items in the section on <a href="#CD011918-sec-0050">Data extraction and management</a>) and pooling was undertaken when studies appeared appropriately similar in terms of wound type, intervention type, outcome measurement time and outcome type, such that synthesis was considered viable. </p> <p>In terms of meta‐analytical approach, when we considered meta‐analysis viable in the presence of clinical heterogeneity (review author judgement) or evidence of statistical heterogeneity, or both, we used a random‐effects model. We considered a fixed‐effect approach only when clinical heterogeneity was thought to be minimal and statistical heterogeneity was estimated as non‐statistically significant for the Chi² value and 0% for the I² assessment (<a href="./references#CD011918-bbs2-0101" title="KontopantelisE , SpringateDA , ReevesD . A re‐analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta‐analyses. PLoS One2013;26:e69930. ">Kontopantelis 2012</a>). This approach was adopted because it is recognised that statistical assessments can miss potentially important between‐study heterogeneity in small samples hence the preference for the more conservative random‐effects model (<a href="./references#CD011918-bbs2-0101" title="KontopantelisE , SpringateDA , ReevesD . A re‐analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta‐analyses. PLoS One2013;26:e69930. ">Kontopantelis 2012</a>). Where clinical heterogeneity was thought to be acceptable or of interest we conducted meta‐analyses even when statistical heterogeneity was high, and attempted to interpret the causes behind this heterogeneity, using pre‐defined sensitivity analyses and pre‐specified subgroup analyses (see below); if we had had sufficient studies, we would have considered using meta‐regression for that purpose, but there were too few studies (<a href="./references#CD011918-bbs2-0134" title="ThompsonSG , SharpSJ . Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine1999;18(20):2693‐708. ">Thompson 1999</a>; <a href="./references#CD011918-bbs2-0135" title="ThompsonSG , HigginsJP . How should meta‐regression analyses be undertaken and interpreted?. Statistics in Medicine2002;21(11):1559‐73. ">Thompson 2002</a>). </p> <p>We have presented data using forest plots where possible. For dichotomous outcomes, we have presented the summary estimate as a risk ratio (RR) with 95% CI. If we had had more than one study reporting continuous outcomes measured in the same way across studies, we would have presented a pooled mean difference (MD) with 95% CI; we would have pooled standardised mean difference (SMD) estimates if studies measured the same outcome using different magnitude scales. However, we did not identify more than one study reporting particular continuous outcomes. For time‐to‐event data, we reported estimates of hazard ratios and 95% CIs, either as presented in the study reports, or as calculated by us using alternative data (<a href="./references#CD011918-bbs2-0136" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(16). [DOI: 10.1186/1745‐6215‐8‐16] ">Tierney 2007</a>). If we had identified more than one study reporting time‐to‐event data, we would have pooled the hazard ratios and their standard errors using the generic inverse variance method in <a href="./references#CD011918-bbs2-0126" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>. If there had been any studies in which time to healing was analysed as a continuous measure, but not all ulcers were healed or it was not clear if all ulcers were healed, we would have documented use of the outcome in the study, but data would not have been summarised or used in any meta‐analysis. However, no studies were found with outcomes of this type. </p> <p>We obtained pooled estimates of treatment effect using <a href="./references#CD011918-bbs2-0126" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>. </p> </section> <section id="CD011918-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we included all studies in the analysis, and for the primary outcomes carried out a sensitivity analysis, excluding from the analysis studies at overall high risk of bias, provided this did not reduce the analysis to one study. </p> <p>If there was heterogeneity in the primary outcome of complete healing, we investigated it using the following pre‐specified subgroup analyses, provided there were at least two studies per subgroup: </p> <p> <ul id="CD011918-list-0010"> <li> <p>presence versus absence of compression treatment</p> </li> <li> <p>comparator treatments as basic contact dressings versus advanced wound dressings</p> </li> <li> <p>silver‐containing treatments versus non silver‐containing treatments</p> </li> <li> <p>infected ulcers versus non‐infected ulcers at baseline; preferably this subgroup analysis was at the study level (all participants with, or all participants without infection at baseline) or the subgroup analysis was based on the authors' pre‐specified within‐trial analyses </p> </li> <li> <p>duration of leg ulcer (12 months or more versus less than 12 months); because it is suggested that hard‐to‐heal ulcers (such as those of a longer duration) have higher protease activity and thus will respond better to PMM treatments (relative to control), compared with wounds of shorter duration. A duration of 12 months or more is an independent risk factor for harder‐to‐heal wounds (<a href="./references#CD011918-bbs2-0108" title="MargolisDJ , Allen‐TaylorL , HoffstadO , BerlinJA . The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair and Regeneration2004;12(2):163‐8. ">Margolis 2004</a>). Preferably this subgroup analysis was based on pre‐specified within‐trial analyses performed by study authors. In the absence of this, we intended to consider between‐trial subgroup analyses on the basis of the median duration of leg ulcer in the study, provided there were at least two studies per subgroup. </p> </li> </ul> </p> <p>We conducted the standard test for homogeneity across subgroup results (rather than across individual study results) as part of the assessment of the credibility of the subgroup analyses: an I² statistic was computed for subgroup differences; this describes the percentage of the variability in effect estimates from the different subgroups that is due to genuine subgroup differences rather than sampling error (chance) (<a href="./references#CD011918-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD011918-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>If there was heterogeneity, we carried out a sensitivity analysis for the outcome of complete healing in which we excluded RCTs classified as being at overall high risk of bias, provided this did not reduce the analysis to one study. </p> <p>For the outcome 'proportion of participants completely healed', we conducted a sensitivity analysis based on available cases. </p> <section id="CD011918-sec-0060"> <h5 class="title">'Summary of findings' tables</h5> <p>We have presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the certainty (formerly, quality) of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD011918-bbs2-0127" title="SchünemannHJ , OxmanAD , Higgins JPT VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>). 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE approach. The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The certainty of a body of evidence involves consideration of within‐study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD011918-bbs2-0128" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>). We have presented the following outcomes in the 'Summary of findings' tables, with a separate table for each key comparison: </p> <p> <ul id="CD011918-list-0011"> <li> <p>time‐to‐complete ulcer healing where analysed using appropriate survival analysis methods </p> </li> <li> <p>proportion of ulcers completely healed during the trial period</p> </li> <li> <p>adverse events.</p> </li> </ul> </p> <p>Where it was not possible to pool the data or if the evidence consisted of single studies, we conducted the GRADE assessment for each comparison and presented this narratively within the results section without the presentation of separate 'Summary of findings' tables. </p> <p>For assessing imprecision, we took into consideration the number of events and the width of the 95% CI with respect to GRADE 'default' values of RR = 1.25 and 0.75. </p> <p>For calculating absolute risk differences for dichotomous and time‐to‐event outcomes, we used the median of the risks in the control groups at particular time points. </p> <p>Elements of this methods section are based on the standard Cochrane Wounds Protocol Template. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011918-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011918-sec-0061"></div> <section id="CD011918-sec-0062"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011918-sec-0147" title="">Characteristics of included studies</a> and <a href="./references#CD011918-sec-0148" title="">Characteristics of excluded studies</a> </p> <section id="CD011918-sec-0063"> <h4 class="title">Results of the search</h4> <p>The search generated 377 records of which we obtained 79 in full text (<a href="#CD011918-fig-0001">Figure 1</a>). We excluded 58 studies (see <a href="./references#CD011918-sec-0148" title="">Characteristics of excluded studies</a>). Nineteen records containing 12 RCTs were eligible for inclusion. One further study is awaiting classification pending further communication from the study authors (see <a href="./references#CD011918-sec-0149" title="">Characteristics of studies awaiting classification</a>). We are also aware of one ongoing study (<a href="./references#CD011918-sec-0150" title="">Characteristics of ongoing studies</a>). </p> <p>We located no new studies by searching reference lists, as any relevant studies had been identified in the electronic searching. </p> </section> <section id="CD011918-sec-0064"> <h4 class="title">Included studies</h4> <p>This review includes 12 studies (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>), which together contained 784 participants. For these studies, the median and range sample sizes were 56.5 (10 to 187). Four studies were reported only as conference abstracts or posters (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>). We contacted the study authors to seek further information on all studies, obtaining information from four (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>): the <a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a> authors gave some further information, but could not supply results data. One study (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>) had three arms, and all the other studies had two. Two studies were conducted in the USA (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>), nine in Europe; in one case it was unclear (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>). The majority of studies were conducted in an outpatient setting. Eleven studies randomised individual participants whilst one (<a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>) randomised legs (i.e. a within‐participant study); this latter study did not take into account pairing either in their analysis or the reporting of their results. No studies randomised clusters of participants. </p> <p>All studies were funded by manufacturers of the PMM treatments, although two studies (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>) stated that their analyses were conducted by independent companies. </p> <section id="CD011918-sec-0065"> <h5 class="title">Participant characteristics</h5> <p>All studies included participants with VLUs. The <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> study also included people with VLUs with aetiologies described as venous (55%), postphlebitic (17%) and with arterial participation (28%); we regarded this as an 'indirect' population. </p> <p>Nine of the 12 studies were in participants described as having 'non‐responsive' or 'hard‐to‐heal' ulcers; explanations are given in the <a href="./references#CD011918-sec-0147" title="">Characteristics of included studies</a>, where information was available; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a> and <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a> did not give sufficient information and in <a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a> the only indicator of 'hard‐to‐heal' was 23% with elevated protease levels. Five studies reported prior treatment of the wounds (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>), one study reported no prior treatment (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) and the other studies did not mention prior treatment. </p> <p>Two studies reported that over 50% of the ulcers were recurrent (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>). </p> </section> <section id="CD011918-sec-0066"> <h5 class="title">Interventions assessed</h5> <p>A range of PMM treatments was evaluated; all were dressings (see below). Four studies (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>) randomised PMM dressings that incorporated silver; we treated these silver‐containing products as a different type of PMM dressing, noting that there may be additional benefits from the combination with silver. </p> <section id="CD011918-sec-0067"> <h6 class="title">Interventions</h6> <p>The following PMM dressings were reported in the included studies:</p> <p> <ul id="CD011918-list-0012"> <li> <p>PMM: collagen/oxidised regenerated cellulose matrix dressing (Promogran ®) ‐ four studies (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002)</a> </p> </li> <li> <p>PMM: collagen dressing ‐ two studies: Suprasorb C ® (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>) and Proheal ® (<a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>) </p> </li> <li> <p>PMM: polyacrylate‐based hydrogel (Hydroclean ®) ‐ one study (<a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>) </p> </li> <li> <p>PMM‐FOAM combination dressing: non‐adherent wound contact dressing (foam) containing nano‐oligosaccharide factor (NOSF; UrgoStart ®) ‐ two studies (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>) </p> </li> <li> <p>PMM‐ALGINATE combination dressing: collagen alginate dressing (Fibracol ®)* ‐ one study (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) </p> </li> <li> <p>PMM‐SILVER: collagen/oxidised regenerated cellulose matrix with silver dressing (Promogran Prisma ®) ‐ three studies (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>) </p> </li> <li> <p>PMM‐SILVER: collagen plus silver dressing ‐ one study (<a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>). </p> </li> </ul> </p> <p>*The product Fibracol is described as protease‐modulating on the Portuguese version of Systagenix’s web site (<a href="./references#CD011918-bbs2-0133" title="SystagenixPortugal . How does it work? [Como funciona?]. www.systagenix.com.br/our‐products/lets‐promote/fibracol‐plus‐307/how‐does‐it‐work (accessed 19 April 2016). ">Systagenix Portugal 2016</a>), which shows a column chart reporting levels of proteases, so it is reasonable to be considered as a PMM dressing. It is not widely available. </p> </section> <section id="CD011918-sec-0068"> <h6 class="title">Comparisons</h6> <p>There were a number of different comparisons, which we have grouped under the following broad headings. Further details are given in <a href="#CD011918-tbl-0002">Table 1</a>: </p> <div class="table" id="CD011918-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparison type*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Intervention group</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary dressing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Secondary dressing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary dressing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Secondary dressing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basic wound contact</p> <p>(BWC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silverR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM + BWC</p> <p>(interfacial dressing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrogel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐alginateE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Comparison types:</p> <p>1. PMM dressing regimen versus basic wound contact dressing regimen</p> <p>2a. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group the same as the primary dressing in the control group </p> <p>2b. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group being similar but different from the primary dressing in the control group </p> <p>2c. PMM dressing regimen versus advanced dressing regimen with the same secondary dressings in both groups or no secondary dressings or secondary dressings only in the control group </p> <p>2d. PMM dressing regimen versus advanced dressing regimen: PMM/advanced combination dressing versus advanced dressing </p> <p>3. PMM dressing 1 versus PMM dressing 2</p> </div> </div> <p> <ol id="CD011918-list-0013"> <li> <p>PMM dressing regimen versus basic wound contact dressing regimen (<a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) </p> </li> <li> <p>PMM dressing regimen versus advanced dressing regimen</p> <ol id="CD011918-list-0014"> <li> <p>with the secondary dressing in the experimental group the same as the primary dressing in the control group (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>). The <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a> study reported additional use of a non‐adherent petrolatum‐impregnated dressing as an interface between the PMM dressing and the secondary dressing, and this was not used in the control group </p> </li> <li> <p>with the secondary dressing in the experimental group being similar but different from the primary dressing in the control group (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>) </p> </li> <li> <p>with the same secondary dressings in both groups or no secondary dressings or secondary dressings only in the control group (<a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>) </p> </li> <li> <p>PMM/advanced dressing combination dressing versus advanced dressing (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) </p> </li> </ol> </li> <li> <p>PMM dressing 1 versus PMM dressing 2 (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>). </p> </li> </ol> </p> <p>In accordance with the protocol, and on clinical advice, we combined comparisons 1, 2a, 2b, 2c and 2d in a single analysis, thereby comparing any PMM dressing regimen with any other (non‐PMM) dressing regimen. This approach was expected to answer the clinically important question regarding whether PMM dressings <i>per se</i> (and as a class) are associated with positive or negative effects relative to other dressings. This assumes that the PMM 'class' not only includes different types of PMM dressing, but also includes combinations of PMM dressing with any other dressing type. It also assumes that secondary dressings are unimportant. </p> <p>Eleven of the 12 studies reported concurrent compression therapy; the <a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a> full paper did not mention compression. We have given further details of compression therapy used in the <a href="./references#CD011918-sec-0147" title="">Characteristics of included studies</a> table. </p> </section> </section> <section id="CD011918-sec-0069"> <h5 class="title">Trial duration</h5> <p>Four studies had a duration of follow‐up of eight weeks or less: <a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> (four weeks); <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a> (two weeks); <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a> and <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a> (eight weeks) and five studies had 12 weeks' follow‐up (<a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>). One study reported results at both four and 12 weeks (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>). One study reported results at six months and graphically at one, two, three, four and five months (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>). The <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a> study was stopped early for benefit in a planned interim analysis; this was at two weeks, assessed on their primary outcome of reduction in the proportion of fibrin and necrosis. </p> </section> <section id="CD011918-sec-0070"> <h5 class="title">Outcomes</h5> <p>Not all 12 studies reported all the outcomes.</p> <p> <ul id="CD011918-list-0015"> <li> <p>Only one study reported sufficient data to allow calculation of time‐to‐complete healing (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) </p> </li> <li> <p>Eight reported the proportion with complete healing (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) </p> </li> <li> <p>Six studies reported on adverse events (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>, <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) </p> </li> <li> <p>Five studies reported pain (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>, <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a> ); five reported infection (<a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>); one study reported quality of life (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>); one study reported resource use (<a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) and one study reported cost data in a German healthcare setting (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>) </p> </li> <li> <p>One study (<a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>) only reported the secondary outcome of change in ulcer size. We dId not report the results for this outcome because the review's primary healing outcomes were reported for this comparison by other studies (as per our protocol) </p> </li> <li> <p>For one study, we are awaiting results from the study authors (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011918-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded 57 studies from the review for the following reasons (see <a href="./references#CD011918-sec-0148" title="">Characteristics of excluded studies</a>): </p> <p> <ul id="CD011918-list-0016"> <li> <p>nine studies were not RCTs (<a href="./references#CD011918-bbs2-0014" title="BoltonLL . Evidence corner: randomized controlled trial of collagen/oxidized regenerated cellulose dressing. Wounds2003;15(6 Suppl):19‐20. ">Bolton 2003</a>; <a href="./references#CD011918-bbs2-0027" title="GardnerS . Using treatment pathways to improve healing of venous leg ulceration. Wounds UK2013;9(1):67‐75. ">Gardner 2013</a>; <a href="./references#CD011918-bbs2-0031" title="HoddeJP , HilesMC , SillingsN , MetzgerDW . Characterization of the local wound environment following treatment of chronic leg ulcers with SIS wound matrix: small intestinal submucosa. 19th Annual Symposium on Advanced Wound Care; 2006 April 30‐May 3; San Antonio (TX). 2006; Vol. 4:105‐6. ">Hodde 2006</a>; <a href="./references#CD011918-bbs2-0032" title="KarimRB , BritoBL , DutrieuxRP , LassanceFP , HageJJ . MMP‐2 assessment as an indicator of wound healing: a feasibility study. Advances in Skin and Wound Care2006;19(6):324‐7. ">Karim 2006</a>; <a href="./references#CD011918-bbs2-0035" title="MetznerB , VanscheidtW , NorgauerJ . Influence of platelet‐derived products on mRNA expression of growth factors, inducible growth related genes, metalloproteinases and their inhibitors in ulcers of patients with chronic venous insufficiency. Australasian Journal of Dermatology1997;38(2 Suppl):175. ">Metzner 1997</a>; <a href="./references#CD011918-bbs2-0036" title="MianE , MartiniP , BeconciniD , MianM . Healing of open skin surfaces with collagen foils. International Journal of Tissue Reactions1992;14(Suppl):27‐34. ">Mian 1992</a>; <a href="./references#CD011918-bbs2-0052" title="RonfardRV , GroverGK . Allogeneic living cell spray: a new concept in the treatment of wounds. Journal of Tissue Engineering and Regenerative Medicine2012;6(Suppl.1):91. [DOI: 10.1002/term.1586] ">Ronfard 2012</a>; <a href="./references#CD011918-bbs2-0053" title="SerraR , BuffoneG , FalconeD , MolinariV , ScaramuzzinoM , GallelliL , et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases‐9 and neutrophil gelatinase‐associated lipocalin. Wound Repair and Regeneration2013;21(3):395‐402. [DOI: 10.1111/wrr.12035] ">Serra 2013</a>; <a href="./references#CD011918-bbs2-0070" title="WollinaU , SchmidtW , KronertC , NelskampC , ScheibeA , FasslerD . Some effects of a topical collagen‐based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations. International Journal of Lower Extremity Wounds2005;4(4):214‐24. ">Wollina 2005</a>); </p> </li> <li> <p>eight studies were in an ineligible or mixed wound population (<a href="./references#CD011918-bbs2-0013" title="AnichiniR , TedeschiA , BerniniA , BarbaneraL , DeBellisA . Detecting and treating Elevated Protease Activity (EPA) in chronic diabetic wounds. EWMA Journal2013;13(1 Suppl):275. ">Anichini 2013</a>; <a href="./references#CD011918-bbs2-0041" title="PalmieriB . Heterologous collagen in wound healing: a clinical study. International Journal of Tissue Reactions1992;14(Suppl):21‐5. ">Palmieri 1992</a>; <a href="./references#CD011918-bbs2-0043" title="RamirezGM , WethersDL , KoshyM , SteinbergMH , PhillipsG , SiegelRS , et al. Accelerated healing of chronic sickle cell leg ulcers treated with a RGD matrix. 19th Annual Meeting of the National Sickle Cell Disease Program; 1994 March; New York. 1994:Abstract 1. ">Ramirez 1994</a>; <a href="./references#CD011918-bbs2-0055" title="ShanahanDR . The Explorer study: the first double‐blind RCT to assess the efficacy of TLC‐NOSF on DFUs. Journal of Wound Care2013;22(2):78‐82. ">Shanahan 2013</a>; <a href="./references#CD011918-bbs2-0056" title="SheehanP , JonesP , CaselliA , GiuriniJM , VevesA . Percent change in wound area of diabetic foot ulcers over a 4‐week period is a robust predictor of complete healing in a 12‐week prospective trial. Diabetes Care2003;26(6):1879‐82. [DOI: 10.2337/diacare.26.6.1879] ">Sheehan 2003</a>; <a href="./references#CD011918-bbs2-0063" title="VevesA . Promogran, a cost‐effective new device for treating chronic ulcers. Diabetic Foot2001;4:S4‐5. ">Veves 2001</a>; <a href="./references#CD011918-bbs2-0064" title="VevesA , SheehanP , PhamHT . A randomized controlled trial of Promogran (a collagen/oxidised regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Archives of surgery2002;137(7):822‐7. ">Veves 2002</a>; <a href="./references#CD011918-bbs2-0068" title="WethersDL , RamirezGM , KoshyM , SteinbergMH , PhillipsG , SiegelRS , et al. Accelerated healing of chronic sickle‐cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Blood1994;84(6):1775‐9. ">Wethers 1994</a>); </p> </li> <li> <p>38 had an ineligible intervention (<a href="./references#CD011918-bbs2-0015" title="BrownA , AugustinM , JungerM , ZuttM , DissemondJ , RabeE , et al. Randomized standard‐of‐care‐controlled trial of a silica gel fibre matrix in the treatment of chronic venous leg ulcers. European Journal of Dermatology2014;24(2):210‐16. [DOI: 10.1684/ejd.2014.2344] ">Brown 2014</a>; <a href="./references#CD011918-bbs2-0016" title="Brown‐EtrisM , ShieldsDK , GalluzziKE , SteinbergJS , ShalenAB , BarnesHR , et al. Preliminary clinical outcomes on the use of composite cultured skin for the healing of venous ulcers. 13th Annual Symposium on Advanced Wound Care; 2000 April 1‐4; Dallas (TX). 2000:D4. ">Brown‐Etris 2000a</a>; <a href="./references#CD011918-bbs2-0017" title="CaprioB , MurgianoGA , RicciE , SicilianoG , ZurleniG . The cost effectiveness of modern dressings in leg ulcer care. 4th European Conference on Advances in Wound Management; 1994 Sept 6‐9; Copenhagen, Denmark. 1995:199. ">Caprio 1995a</a>; <a href="./references#CD011918-bbs2-0019" title="CurranMP , PloskerGL . Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs2002;16(6):439‐55. [DOI: 10.2165/00063030‐200216060‐00005] ">Curran 2002</a>; <a href="./references#CD011918-bbs2-0020" title="DemlingRH , NiezgodaJA , HarawayGD , MostowEN . Small intestinal submucosa wound matrix and full‐thickness venous ulcers: preliminary results. Wounds2004;16(1):18‐22. ">Demling 2004</a>; <a href="./references#CD011918-bbs2-0021" title="EbellM . Is human skin equivalent more effective than Unna paste boots in the treatment of venous ulcers?. Evidence‐Based Practice1998;1(6):1. ">Ebell 1998</a>; <a href="./references#CD011918-bbs2-0022" title="FalabellaAF , CarsonP , EaglsteinWH , FalangaV . The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. Journal of the American Academy of Dermatology1998;39(5):737‐40. ">Falabella 1998</a>; <a href="./references#CD011918-bbs2-0023" title="FalangaV , MargolisD , AlvarezO , AulettaM , MaggiacomoF , AltmanM , et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Archives of Dermatology1998;134(3):293‐300. ">Falanga 1998a</a>; <a href="./references#CD011918-bbs2-0026" title="FalangaV , SaapLJ , OzonoffA . Wound bed score and its correlation with healing of chronic wounds. Dermatologic Therapy2006;19(6):383‐90. [DOI: 10.1111/j.1529‐8019.2006.00096.x] ">Falanga 2006</a>; <a href="./references#CD011918-bbs2-0024" title="FalangaV , SabolinskiM . A bilayered living skin construct (APLIGRAF(TM)) accelerates complete closure of hard‐to‐heal venous ulcers. Wound Repair and Regeneration1999;7(4):201‐7. ">Falanga 1998b</a>; <a href="./references#CD011918-bbs2-0025" title="FalangaVJ . Tissue engineering in wound repair. Advances in Skin and Wound Care2000;13(2 Suppl):15‐19. ">Falanga 2000</a>; <a href="./references#CD011918-bbs2-0028" title="GilliganAM , WaycasterC . Cost‐effectiveness of small intestinal submucosa extracellular matrix on wound closure in patients with difficult‐to‐heal wound of mixed arterial/venous and venous etiology. Value in Health2014;17(3):A272‐3. [DOI: 10.1016/j.jval.2014.03.1587] ">Gilligan 2014</a>; <a href="./references#CD011918-bbs2-0029" title="GoedkoopR , JulietR , YouPHK , DaroczyJ , DeRoosK‐P , LijnenR , et al. Wound stimulation by growth‐arrested human keratinocytes and fibroblasts: HP802‐247, a new‐generation allogeneic tissue engineering product. Dermatology2010;220(2):114‐20. [DOI: 10.1159/000277380] ">Goedkoop 2010</a>; <a href="./references#CD011918-bbs2-0030" title="GravanteG , SorgeR , GiordanN , GeorgescuSR , MorariuSH , StoicescuI , et al. Multicenter clinical trial on the performance and tolerability of the Hyaluronic acid‐collagenase ointment for the treatment of chronic venous ulcers: a preliminary pilot study. European Review for Medical and Pharmacological Sciences2013;17(20):2721‐7. ">Gravante 2013</a>; <a href="./references#CD011918-bbs2-0033" title="LantisJC , MarstonWA , FarberA , KirsnerRS , ZhangY , LeeTD , et al. The influence of patient and wound variables on healing of venous leg ulcers in a randomized controlled trial of growth‐arrested allogeneic keratinocytes and fibroblasts. Journal of Vascular Surgery2013;58(2):433‐9. [DOI: 10.1016/j.jvs.2012.12.055] ">Lantis 2013</a>; <a href="./references#CD011918-bbs2-0034" title="MarstonW , KirsnerR , SnyderR , LeeT , CargillI , SladeH . Variables affecting healing of venous leg ulcers in a randomized, vehicle‐controlled trial of topical cellular therapy. Journal of Vascular Surgery2012;55(1):303. [DOI: 10.1016/j.jvs.2011.11.027] ">Marston 2012</a>; <a href="./references#CD011918-bbs2-0037" title="MoffattCJ , StantonJ , MurrayS , DoodyV , DavisPJ , FranksPJ . A randomised trial to compare the performance of Oxyzyme and Iodozyme with standard care in the treatment of patients with venous and mixed venous/arterial ulceration. Wound Medicine2014;6:1‐10. [DOI: 10.1016/j.wndm.2014.08.002] ">Moffatt 2014</a>; <a href="./references#CD011918-bbs2-0038" title="MorimotoN , YoshimuraK , NiimiM , ItoT , TadaH , TeramukaiS , et al. An exploratory clinical trial for combination wound therapy with a novel medical matrix and fibroblast growth factor in patients with chronic skin ulcers: a study protocol. American Journal of Translational Research2012;4(1):52‐9. ">Morimoto 2012</a>; <a href="./references#CD011918-bbs2-0039" title="MorimotoN , YoshimuraK , NiimiM , ItoT , AyaR , FujitakaJ , et al. Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers. Tissue engineering Part A2013;19(17‐18):1931‐40. [DOI: 10.1089/ten.tea.2012.0634] ">Morimoto 2013</a>; <a href="./references#CD011918-bbs2-0040" title="MostowEN , HarawayGD , DalsingM , HoddeJP , KingD , OASIS Venus Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. Journal of Vascular Surgery2005;41(5):837‐43. [DOI: 10.1016/j.jvs.2005.01.042] ">Mostow 2005</a>; <a href="./references#CD011918-bbs2-0042" title="PlaninsekRT , LunderT . Stimulation of venous leg ulcers with thrombocytic growth factors: a randomised study. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:62. ">Planinsek 2007</a>; <a href="./references#CD011918-bbs2-0044" title="RobsonMC , PhillipLG , CooperDM , LyleWG , RobsonLE , OdomL , et al. Safety and effect of transforming growth factor‐beta(2) for treatment of venous stasis ulcers. Wound Repair and Regeneration1995;3(2):157‐67. ">Robson 1995</a>; <a href="./references#CD011918-bbs2-0046" title="RomanelliM , DiniV , BrilliC , BertoneM . Oasis wound matrix versus hyaluronic acid in the treatment of difficult‐to‐heal wounds of mixed arterial/venous aetiology. 19th Annual Symposium on Advanced Wound Care &amp; 16th Medical Research Forum on Wound Repair; 2006 April 30‐May 3; San Antonio, Texas, USA; Ostomy Wound Manage. 2006; Vol. 52. ">Romanelli 2006b</a>; <a href="./references#CD011918-bbs2-0047" title="RomanelliM , DiniV , BertoneM , BarbaneraS , BrilliC . OASIS wound matrix versus Hyaloskin in the treatment of difficult‐to‐heal wounds of mixed arterial/venous aetiology. International Wound Journal2007;4(1):3‐7, 39‐40. [DOI: 10.1111/j.1742‐481X.2007.00300.x] ">Romanelli 2007</a>; <a href="./references#CD011918-bbs2-0045" title="RomanelliM , EllerveeT , JarveH , KahaE . Amelogenins (Xelma) in hard‐to‐heal venous leg ulcers, an open regime investigation. 16th Conference of the European Wound Management Association; 2006 May 18‐20; Prague, Czech Republic. 2006:143. ">Romanelli 2006a</a>; <a href="./references#CD011918-bbs2-0049" title="RomanelliM , VowdenP , PriceP . An open, randomised, comparative, parallel group, multi‐centre clinical trial of amelogenin extracellular matrix therapy in the treatment of hard‐to‐heal venous leg ulcers: follow‐up data. 3rd Congress of the World Union of Wound Healing Societies; 2008 June 4‐8; Toronto, Canada2008:Abstract OR100. ">Romanelli 2008b</a>; <a href="./references#CD011918-bbs2-0048" title="RomanelliM , KahaE , StegeH , WnorowskiJW , VowdenP , MajamaaH , et al. Effect of amelogenin extracellular matrix protein and compression on hard‐to‐heal venous leg ulcers: follow‐up data. Journal of Wound Care2008;17(1):17‐8, 20‐3. ">Romanelli 2008a</a>; <a href="./references#CD011918-bbs2-0050" title="RomanelliM , DiniV , BertoneMS . Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult‐to‐heal wounds of mixed arterial/venous etiology. Advances in Skin and Wound Care2010;23(1):34‐8. [DOI: 10.1097/01.ASW.0000363485.17224.26] ">Romanelli 2010</a>; <a href="./references#CD011918-bbs2-0051" title="RomanelliM , DiniV , BertoneM . Histological evaluation of venous leg ulcers treated with amelogenin. EWMA Journal2011;11(2 Suppl):224. ">Romanelli 2011</a>; <a href="./references#CD011918-bbs2-0054" title="SerraR , GallelliL , ContiA , DeCaridiG , MassaraM , SpinelliF , et al. The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Design, Development and Therapy2014;8:519‐27. [DOI: 10.2147/DDDT.S61770] ">Serra 2014</a>; <a href="./references#CD011918-bbs2-0057" title="SmithBA . The dressing makes the difference. Trial of two modern dressings on venous ulcers. Professional Nurse1994;9(5):348, 350‐2. ">Smith 1994</a>; <a href="./references#CD011918-bbs2-0058" title="StojadinovicO , RamirezH , PatelS , YinN , BollenbachT , GoldenP , et al. Genomic insight into molecular mechanisms of action of bilayered living cellular construct nonhealing venous leg ulcers. Wound Repair and Regeneration2014;22(2):A60. [DOI: 10.1111/wrr.12155] ">Stojadinovic 2014</a>; <a href="./references#CD011918-bbs2-0059" title="ThomasS , BanksV , FearM , HagelsteinS , BaleS , HardingK . A study to compare two film dressings used as secondary dressings. Journal of Wound Care1997;6(7):333‐6. ">Thomas 1997</a>; <a href="./references#CD011918-bbs2-0060" title="Trial C, DarbasH , LavigneJP , SottoA , SimoneauG , TilletY , et al. Assessment of the antimicrobial effectiveness of a new silver alginate wound dressing: a RCT. Journal of Wound Care2010;19(1):20‐6. ">Trial 2010</a>; <a href="./references#CD011918-bbs2-0061" title="VareliasA , HughesH , CowinA , CowledP , CooterR , HarriesR , et al. Detection and modulation of matrix metalloproteinases in patients with chronic leg ulcers treated with whey‐derived growth factors. Fourth Australian Wound Management Association Conference; 2002 March 7‐10; Adelaide, South Australia. 2002:34. ">Varelias 2002</a>; <a href="./references#CD011918-bbs2-0065" title="VowdenP , RomanelliM , PeterR , BoströmA , JosefssonA , StegeH . The effect of amelogenins (XELMA) on hard‐to‐heal venous leg ulcers. Wound Repair and Regeneration2006;14(3):240‐6. [DOI: 10.1111/j.1743‐6109.2006.00117.x] ">Vowden 2006</a>; <a href="./references#CD011918-bbs2-0066" title="VowdenP , RomanelliM . Effect of amelogenin matrix protein solution as add‐on treatment to compression in hard‐to‐heal venous leg ulcers: a randomised controlled trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:54. ">Vowden 2007a</a>; <a href="./references#CD011918-bbs2-0067" title="VowdenP , RomanelliM , PriceP . Effect of amelogenin extracellular matrix protein and compression on hard‐to‐heal venous leg ulcers. Journal of Wound Care2007;16(5):189‐95. ">Vowden 2007b</a>). The majority of these studies investigated skin substitutes/bioengineered matrix treatments; </p> </li> <li> <p>two studies did not report a relevant outcome and healing was not the objective of the trial (<a href="./references#CD011918-bbs2-0018" title="ChalonerD , FletcherM , MilwardP . Clinical trials: comparing dressings. Nursing Standard1992;7(7):9‐11. ">Chaloner 1992</a>; <a href="./references#CD011918-bbs2-0062" title="VareliasA , CowinAJ , AdamsD , HarriesRHC , CooterRD , BelfordDA , et al. Mitogenic bovine whey extract modulates matrix metalloproteinase‐2, ‐9, and tissue inhibitor of matrix metalloproteinase‐2 levels in chronic leg ulcers. Wound Repair and Regeneration2006;14(1):28‐37. [DOI: 10.1111/j.1743‐6109.2005.00085.x] ">Varelias 2006</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011918-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD011918-fig-0002">Figure 2</a> shows risk of bias judgements for each study (and by outcome for attrition and outcome assessor blinding). Judgements for each domain across studies are shown in <a href="#CD011918-fig-0003">Figure 3</a>. We itemised blinding of outcome assessors separately for the healing outcomes, adverse events and secondary outcomes (pain and infection); risk of attrition bias was reported separately for adverse events and other outcomes. We have displayed risk of bias assessments for the studies in each analysis at the side of each forest plot, but only the domains contributing to overall risk of bias are shown. We have given further information on each risk of bias item in the <a href="./references#CD011918-sec-0147" title="">Characteristics of included studies</a>. </p> <section id="CD011918-sec-0073"> <h4 class="title">Overall risk of bias</h4> <p>We assessed overall risk of bias in terms of high risk of bias in one or more domains from selection bias, detection bias (outcome assessor not blinded), and attrition bias. </p> <p> <ul id="CD011918-list-0017"> <li> <p>For the healing outcomes, we considered six studies (of nine) to have high overall risk of bias (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>), two of which had two domains of high risk of bias (<a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008;</a><a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>). </p> </li> <li> <p>For adverse events, four studies (of six) had high overall risk of bias (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>); one of which had two domains (<a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>). </p> </li> <li> <p>For the secondary outcomes, six studies (of eight) had high risk of bias (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>); three of which had two domains (<a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011918-sec-0074"> <h3 class="title" id="CD011918-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD011918-tbl-0001"><b>Summary of findings for the main comparison</b> Protease‐modulating matrix dressing regimen compared to any other dressing regimen for healing venous leg ulcers</a> </p> <p>See: <a href="./full#CD011918-tbl-0001">summary of findings Table for the main comparison</a> and <a href="#CD011918-tbl-0003">Table 2</a> for extracted outcome data. In this section, we report the effects of any PMM dressing regimen versus any comparison dressing regimen. </p> <div class="table" id="CD011918-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison type*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions (dressings)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Length of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion healed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to healing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion with pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion with infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resource use</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a and 2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + foam (n = 4);</p> <p>Group 2: foam (n = 4)</p> <p>Group 3: basic wound contact (n = 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/4 Group 2: 0/4 Group 3: 0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/4 Group 2: 0/4 Group 3: 4/4</p> <p>Peto OR for 1 vs 3: 0.03 (95% CI 0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM1 (n = 32);</p> <p>Group 2: PMM2 (n = 32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐silver + hydrocolloid (n = 22);</p> <p>Group 2: hydrocolloid (n = 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks and 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks Group 1: 5/22</p> <p>Group 2: 3/27</p> <p>RR 2.05 (95% CI 0.55 ‐ 7.63)</p> <p>12 weeks </p> <p>Group 1: 14/22</p> <p>Group 2:</p> <p>16/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No results reported (though in protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No results reported (though in protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No results reported (though in protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM (n = 34);</p> <p>Group 2: hydrogel (n = 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 15/34</p> <p>Group 2: 18/41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 7/32</p> <p>Group 2: 0/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/32</p> <p>Group 2: 2/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐silver + foam (n = 15);</p> <p>Group 2: foam (n = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 11/15</p> <p>Group 2: 7/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 4/15</p> <p>Group 2: 5/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐silver (n = 10);</p> <p>Group 2: hydrocolloid + silver (n = 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 3/10</p> <p>Group 2: 5/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/10</p> <p>Group 2: 0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐foam (n = 93);</p> <p>Group 2: foam (n = 94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 6/93</p> <p>Group 2: 7/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 29/89</p> <p>Group 2: 27/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 1/89 Group 2: 1/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 7/89</p> <p>Group 2: 6/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EQ‐5D:</b> </p> <p>Pain/discomfort:</p> <p>Group 1: mean 1.53 (SD 0.53) n = 89</p> <p>Group 2: 1.74 (0.65) n = 88</p> <p>MD: ‐0.21 (95% CI ‐0.38 to ‐0.04)</p> <p>Anxiety/depression:</p> <p>1.35 (0.53) and 1.54 (0.60)</p> <p>MD: ‐0.19 (95% CI ‐0.36 to ‐0.02) numbers analysed assumed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean total treatment costs over 8 weeks (Germany):</p> <p>Group 1: EUR 557.51</p> <p>Group 2: EUR 526.19</p> <p>Cost effectiveness analysis was based on number with at least 40% wound area reduction and so are not reported here </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐alginate</p> <p>Group 2: alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months: Group 1: 34/50</p> <p>Group 2:</p> <p>32/50</p> <p>RR: 1.06 (95% CI 0.80 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graph of cumulative number of healed ulcers. HR calculated (<a href="./references#CD011918-bbs2-0136" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(16). [DOI: 10.1186/1745‐6215‐8‐16] ">Tierney 2007</a>): 1.21 (95% CI 0.75 to 1.97), assuming no censoring </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL/Resources not reported.</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Number healed at other times (from graph); 50 randomised per group):</p> <p>1 month: 2 and 0</p> <p>2 months: 12 and 8</p> <p>3 months: 26 and 20</p> <p>4 months: 29 and 22</p> <p>5 months: 34 and 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + basic wound contact dressing + alginate (n = 20);</p> <p>Group 2: alginate (n = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 6/20 Group 2: 5/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/20</p> <p>Group 2: 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/20 Group 2: 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM1 (n = 57);</p> <p>Group 2: PMM2 (n = 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 10/57</p> <p>Group 2: 8/60</p> <p>RR: 1.32 (95% CI 0.56 to 3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 14/46</p> <p>Group 2: 23/49</p> <p>RR: 0.65 (95% CI 0.38 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 4/40</p> <p>Group 2: 12/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 1/40</p> <p>Group 2: 6/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + hydrocolloid (n = 17);</p> <p>Group 2: hydrocolloid (n = 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + basic wound contact dressing (n = 37);</p> <p>Group 2: basic wound contact dressing (n = 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 18/37</p> <p>Group 2: 12/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 5/30 Group 2: 5/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe pain:</p> <p>Group 1: 6/27</p> <p>Group 2: 3/24</p> <p>Constant pain: Group 1: 7/27 Group 2: 4/24</p> <p>RR: 1.56 (95% CI 0.52 to 4.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/27</p> <p>Group 2: 5/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline vials per treatment: <br/> Group 1: mean 1.06 (SD 0.78)<br/> Group 2: mean 1.27 (SD 0.78) </p> <p>MD: ‐0.21 (95% CI ‐0.31 to ‐0.11)</p> <p>Number of gauzes: </p> <p>Group 1: 3.8 (2.5)</p> <p>Group 2: 3.7 (2.2)</p> <p>MD: 0.10 (95% CI ‐0.17 to 0.37)</p> <p>(SD 201) seconds</p> <p>MD: ‐40.0 (95% CI ‐128.9 to 48.9)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Comparison types:</p> <p>1. PMM dressing regimen versus basic wound contact dressing regimen</p> <p>2a. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group the same as the primary dressing in the control group </p> <p>2b. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group being similar but different from the primary dressing in the control group </p> <p>2c. PMM dressing regimen versus advanced dressing regimen with the same secondary dressings in both groups or no secondary dressings or secondary dressings only in the control group </p> <p>2d. PMM dressing regimen versus advanced dressing regimen: PMM/advanced combination dressing versus advanced dressing </p> <p>3. PMM dressing 1 versus PMM dressing 2</p> </div> </div> <section id="CD011918-sec-0075"> <h4 class="title">1. Comparison of PMM dressing regimens versus other dressing regimens (nine trials, 503 participants) </h4> <p>We investigated whether any dressing regimen that incorporated a PMM was more effective than any other (non‐PMM) dressing regimen; the term 'regimen' includes primary and secondary dressings, as appropriate. Therefore, we combined the results from nine studies (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>). A tenth study (<a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>) reported none of the primary outcomes. One study (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) reported the proportion with complete healing at six time points, which we used to calculate a hazard ratio, assuming there was no censoring. </p> <section id="CD011918-sec-0076"> <h5 class="title">1.1. Results</h5> <section id="CD011918-sec-0077"> <h6 class="title">Primary outcomes: complete wound healing and adverse events</h6> <section id="CD011918-sec-0078"> <p><b>Time‐to‐complete healing</b></p> <p><i>Low‐certainty evidence</i> from one study (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) (100 participants, of whom 66 healed at 6 months' follow‐up) is unclear whether PMM dressings heal wounds quicker than alginate dressings (HR 1.21, 95% CI 0.74 to 1.97; <a href="#CD011918-tbl-0003">Table 2</a>). The 95% CI is consistent with both clinically important benefit and clinically important harm, and the evidence certainty was downgraded for imprecision (twice). </p> </section> <section id="CD011918-sec-0079"> <p><b>Proportion healed</b></p> <p>Short‐term follow‐up ‐ four to eight weeks: it is unclear whether there is a difference in the probability of healing between PMM dressing regimens and other dressing regimens, because the <i>evidence is of very low certainty</i> (downgraded for risk of bias and imprecision (twice)); RR 0.73 (95% CI 0.34 to 1.58) (random effects) (2 studies (<a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>); 207 participants, of whom 21 healed; <a href="./references#CD011918-fig-0004" title="">Analysis 1.1</a>). </p> <p>Medium‐term follow‐up ‐ 12 weeks: <i>low‐certainty evidence</i> from four studies (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) (192 participants, of whom 89 healed) is unclear whether PMM dressing regimens increase the probability of healing compared with other dressing regimens at 12 weeks' follow‐up (RR 1.28, 95% CI 0.95 to 1.71; <a href="./references#CD011918-fig-0005" title="">Analysis 1.2</a>); the 95% CI is consistent with both clinically important benefit and no difference. Evidence certainty was downgraded for risk of bias and imprecision. </p> <p>Long‐term follow‐up ‐ six months: <i>low‐certainty evidence</i> from one study (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) (100 participants, of whom 66 healed) is unclear whether there is a difference in healing at six months between PMM dressings and other dressings (RR 1.06, 95% CI 0.80 to 1.41; <a href="#CD011918-tbl-0003">Table 2</a>); the 95% CI is consistent with both no difference and clinically important benefit, and the evidence certainty was downgraded twice for imprecision. </p> </section> <section id="CD011918-sec-0080"> <p><b>Adverse events</b></p> <p><i>Low‐certainty evidence</i> from five studies (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) (363 participants, of whom 99 had at least one adverse event) is unclear whether there is a difference between PMM dressing regimens and other dressing regimens in adverse events (RR 1.03, 95% CI 0.75 to 1.42; <a href="./references#CD011918-fig-0006" title="">Analysis 1.3</a>); the 95% CI is consistent with both a clinically important benefit and a clinically important harm. Data were pooled across all durations. Evidence certainty was downgraded for imprecision (twice). </p> </section> </section> <section id="CD011918-sec-0081"> <h6 class="title">Secondary outcomes: pain, infection, quality of life, resource use</h6> <section id="CD011918-sec-0082"> <p><b>Pain</b></p> <p>It is unclear whether there is a difference in the risk of pain between PMM dressing regimens and other dressing regimens, because the <i>evidence is of very low certainty</i> (downgraded for risk of bias, inconsistency (twice) and imprecision (twice)); (5 studies (<a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a>; <a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>); 356 participants, of whom 22 had pain; <a href="./references#CD011918-fig-0007" title="">Analysis 1.4</a>). Results were not pooled because of the different types of pain measured and durations of follow‐up. There is substantial heterogeneity, which may be due to differences in the comparator dressings. </p> </section> <section id="CD011918-sec-0083"> <p><b>Infection</b></p> <p>It is unclear whether there is a difference in the risk of infection between PMM dressing regimens and other dressing regimens, because the <i>evidence is of very low certainty</i> (downgraded for risk of bias, inconsistency and imprecision (twice)); RR 0.69 (95% CI 0.29 to1.68) (5 studies (<a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>); 349 participants, of whom 29 had infection; <a href="./references#CD011918-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD011918-sec-0084"> <p><b>Quality of life</b></p> <p>It is unclear whether there is a difference in quality of life between PMM dressing regimens and other dressing regimens, because the <i>evidence is of very low certainty</i> (downgraded for risk of bias, indirectness and imprecision). Two sub‐scales of EQ 5D were selectively reported on the basis of statistical significance: pain‐discomfort sub‐scale: MD ‐0.21 (95% CI ‐0.38 to ‐0.04); anxiety‐depression sub‐scale, MD ‐0.19 (95% CI ‐0.36 to ‐0.02) (scale 1 to 5, high as poor outcome) (1 study (<a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a>), 177 participants). However, these results are not meaningful because the 5 points on the scale are not intended to be used arithmetically (<a href="./references#CD011918-bbs2-0085" title="VanReenenM , JanssenB . EQ‐5D‐5L User Guide. www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ‐5D‐5L_UserGuide_2015.pdf (accessed 30 March 2015). ">Euroqol 2015</a>). </p> </section> <section id="CD011918-sec-0085"> <p><b>Resource use</b></p> <p><i>Low‐certainty evidence</i> from one study (<a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) (73 participants; <a href="#CD011918-tbl-0003">Table 2</a>) is unclear whether resource use is lower with the PMM dressing than the other dressing. For the participants who used the dressings allocated at randomisation throughout the study, there were 619 and 529 dressing changes for the PMM dressing compared with the other dressing. Number of vials of saline: MD per treatment ‐0.21 (95% CI ‐0.31 to ‐0.11). Number of gauzes used: MD 0.10 (95% CI ‐0.17 to 0.37). Time to complete a dressing change: MD = ‐40 seconds (95% CI ‐62.4 to ‐16.8). The evidence was downgraded for risk of bias (twice). </p> </section> <section id="CD011918-sec-0086"> <p><b>Costs</b></p> <p><i>Low‐certainty evidence</i> from a cost‐effectiveness analysis based on data from <a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a> (187 participants; <a href="#CD011918-tbl-0003">Table 2</a>) in a German healthcare setting is uncertain whether there is a difference in mean total treatment costs. Results are EUR 557.51 for the PMM dressing and EUR 526.19 for the other dressing (mean difference 31.32 EUR higher) after eight weeks of treatment; no standard deviations were reported. The cost effectiveness analysis was based on the number of participants with at least 40% wound area reduction (rather than the number with complete healing) and so results are not reported here. The evidence was downgraded for imprecision (twice). </p> </section> </section> </section> <section id="CD011918-sec-0087"> <h5 class="title">1.2. Summary</h5> <p>Overall, <i>low‐certainty evidence</i> (downgraded for risk of bias and imprecision) is unclear whether PMM dressing regimens are either quicker or more likely to heal VLUs at four to eight weeks, 12 weeks or longer‐term follow‐up than other dressing regimens. </p> <p>The evidence for any difference in the rate of adverse events is similarly uncertain. It is unclear whether there is a difference in pain, infection and quality of life. Finally, there is uncertainty around resource use (vials of saline, dressing changes, and the number of gauzes used) and around mean total costs in a German healthcare system (<a href="./full#CD011918-tbl-0001">summary of findings Table for the main comparison</a> and <a href="#CD011918-tbl-0003">Table 2</a>). </p> </section> </section> <section id="CD011918-sec-0088"> <h4 class="title">2. Comparison of two different PMM dressing regimens (one trial; 117 participants)</h4> <p>One study (n = 117) directly compared two different PMM dressings, non‐adherent wound contact dressing containing NOSF (UrgoStart) and collagen/oxidised regenerated cellulose matrix (Promogran), over 12 weeks (medium term) (<a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>) and a second study (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>) compared two PMM dressings but did not report the results per group. We downgraded the certainty of the evidence from the <a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> study for indirectness because some of the participants had leg ulcers that the authors classified as other than venous (17% were postphlebitic and 28% had arterial participation (see <a href="#CD011918-sec-0064">Included studies</a>). </p> <section id="CD011918-sec-0089"> <h5 class="title">2.1. Results</h5> <section id="CD011918-sec-0090"> <h6 class="title">Primary outcomes: complete wound healing and adverse events</h6> <section id="CD011918-sec-0091"> <p><b>Time‐to‐complete healing</b></p> <p>No studies reported the time‐to‐complete healing outcome.</p> </section> <section id="CD011918-sec-0092"> <p><b>Proportion healed</b></p> <p>Medium‐term follow‐up ‐ 12 weeks: it is unclear whether there is a difference between UrgoStart and Promogran in healing rates at 12 weeks' follow‐up because the <i>evidence is of very low certainty</i> (downgraded for risk of bias (twice), indirectness and imprecision (twice)); RR 1.32 (95% CI 0.56 to 3.10) (1 study (<a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>); 117 participants, of whom 18 healed; <a href="#CD011918-tbl-0003">Table 2</a>). </p> </section> <section id="CD011918-sec-0093"> <p><b>Adverse events</b></p> <p>Medium‐term follow‐up ‐ 12 weeks: it is unclear whether there is a difference in adverse events because the <i>evidence is of very low certainty</i> (as above); RR 0.65 (95% CI 0.38 to 1.10) (1 study (<a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a>); 95 participants for this outcome, in whom 37 had adverse events, which included pain and infection). </p> </section> </section> <section id="CD011918-sec-0094"> <h6 class="title">Secondary outcomes</h6> <p><a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> also reported on pain between dressing changes and infection (<a href="#CD011918-tbl-0003">Table 2</a>). The <i>evidence certainty is very low</i> (downgraded for risk of bias (twice), indirectness and imprecision (twice)). RR for pain: 0.30 (95% CI 0.11 to 0.85); RR for infection is 0.15 (95% CI 0.02 to 1.19). </p> </section> </section> <section id="CD011918-sec-0095"> <h5 class="title">2.2. Summary</h5> <p>There is too much uncertainty to determine whether there is a difference between two different types of PMM dressing (UrgoStart and Promogran) in the rates of healing, adverse events, pain and infection. </p> </section> </section> <section id="CD011918-sec-0096"> <h4 class="title">3. Subgroup and Sensitivity analyses</h4> <p>We conducted prespecified sensitivity and subgroup analyses (see section: <a href="#CD011918-sec-0058">Subgroup analysis and investigation of heterogeneity</a>) for the medium‐term healing outcome because there was a small amount of variability in the point estimates, and a sensitivity analysis for the short‐term healing outcome for the comparison, PMM dressing regimens versus other dressing regimens. </p> <section id="CD011918-sec-0097"> <h5 class="title">Sensitivity analyses</h5> <p>For the medium‐term outcome, three of the four studies were at overall high risk of bias (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>; <a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a>; <a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a>) so risk of bias could not be examined, either for this outcome or for the short‐term outcome (which only had two studies). </p> <p>Sensitivity analysis, assuming an available case analysis, was conducted (<a href="./references#CD011918-fig-0009" title="">Analysis 1.6</a>) and gave a risk ratio of 0.72 (95% CI 0.33 to 1.56) for the short‐term outcome and 1.26 (95% CI 0.96 to 1.64) for the medium‐term outcome. The results of these analyses were very similar to the imputed intention‐to‐treat analyses. </p> </section> <section id="CD011918-sec-0098"> <h5 class="title">Subgroup analyses</h5> <p>Subgroup analyses could only be conducted for the medium‐term outcome. Of the pre‐specified subgroup analyses, only the comparison of silver‐containing PMM treatments versus non silver‐containing treatments gave subgroups with more than one study in each subgroup. The results of this analysis are shown in <a href="./references#CD011918-fig-0010" title="">Analysis 1.7</a>. the test for subgroup differences gives I² = 0% and P = 0.68, and the RR for each subgroup was: silver‐containing PMM subgroup, RR = 1.22 (95% CI 0.85 to 1.75) and no silver subgroup, RR = 1.39 (95% CI 0.85 to 2.29). There was no heterogeneity in either subgroup. </p> <p>As a result of these sensitivity and subgroup analyses, we continued with the original analyses. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011918-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011918-sec-0099"></div> <section id="CD011918-sec-0100"> <h3 class="title" id="CD011918-sec-0100">Summary of main results</h3> <p>The review includes 12 RCTs involving a total of 784 participants, however two of these studies (<a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a>; <a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a>) did not report results for any of the outcomes prespecified for this review. Of the studies reporting outcomes relevant to this review, nine compared PMM dressing regimens with other dressing regimens, whilst one directly compared two PMM dressing regimens. All studies for which we had relevant outcome data also gave the participants compression bandaging. All but two of these studies (<a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>) were in participants described as having 'non‐responsive' or 'hard‐to‐heal' ulcers. </p> <p>For the overall estimates of effectiveness and safety, we summarised results from nine studies; seven of these reported healing outcomes. The main findings reported here are for the comparison of a regimen that includes a PMM dressing versus a regimen with other (non‐PMM) dressings. This is a broad comparison that has a number of assumptions: firstly, that all PMM dressings can be treated as a single class and, secondly, that the nature of the comparator dressings is unimportant. We discuss these assumptions below (<a href="#CD011918-sec-0101">Overall completeness and applicability of evidence</a>). </p> <p>The evidence for the effects of PMM on healing is of low or very low certainty (see <a href="#CD011918-sec-0102">Quality of the evidence</a>). The main results are that in the short term (4 to 8 weeks), the evidence is of very low certainty. In the medium term (12 weeks), it is unclear whether there is a benefit in using a PMM dressing regimen, compared with other dressing regimens: meta‐analysis of four studies in 192 participants gave a RR of 1.28 (95% CI 0.95 to 1.71), which corresponds to an absolute risk difference of 112 more people healed per 1000 (from 20 fewer to 284 more) over 12 weeks (for a median control group risk of 400 per 1000). Low‐certainty evidence from a single study (100 participants) at longer term (6 months) is unclear whether there is a difference between PMM dressing regimens and other dressing regimens (RR 1.06, 95% CI 0.80 to 1.41). Low‐certainty evidence from the same study is uncertain whether wounds treated with PMM‐containing dressing regimens heal quicker than other dressing regimens. The HR is 1.21(95% CI 0.74 to 1.97) and the median time to healing is estimated to be 1.5 months quicker for PMM dressing regimens. However, the 95% CI for the HR is consistent with both clinically important benefit and clinically important harm, and the findings are uncertain. </p> <p>Low‐certainty evidence (5 studies, 363 participants) on adverse events across all durations of follow‐up is unclear whether there is a difference in adverse events between dressing regimens that do, and do not incorporate PMM (RR 1.03, 95% CI 0.75 to 1.42). It is unclear whether there is a difference for the specific adverse events of pain and infection, as well as quality of life because the evidence is of very low certainty. </p> <p>For resource use, low certainty evidence from one study (73 participants) of 12 weeks duration is unclear whether there is a difference between PMM dressing regimens and other dressing regimens in the use of saline vials and the time taken to complete dressing changes; mean differences were fairly small (0.21 vials per treatment and 40 seconds). For costs, low‐certainty evidence from one study (187 participants) of eight weeks' duration is unclear whether there is a difference in total costs per person for the PMM dressing regimen (mean difference versus control = 31 EUR) in a German healthcare system. </p> </section> <section id="CD011918-sec-0101"> <h3 class="title" id="CD011918-sec-0101">Overall completeness and applicability of evidence</h3> <p>The evidence on PMM treatments is fairly limited: the ten relevant studies were generally small, with numerically few events. The population covered was also limited: participants in all studies but two (<a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a>; <a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>), which gave no details, were described as having non‐responsive or 'hard‐to‐heal' ulcers. Therefore, the findings of the review may only be directly relevant to people with ulcers which are in some way hard to heal and who are also receiving compression treatment. </p> <p>We have investigated healing at three pre‐specified time durations and also as a time‐to‐event analysis. Different studies with different characteristics (see below) inform the different durations, and both the time‐to‐event data and any inference regarding time dependence is reliant on a single study. </p> <p>We treated all PMM dressing regimens as a single 'class', but there were several variations, including the type of PMM dressing and the presence or absence of secondary dressings and their type: the evidence for the medium‐term (12‐week) healing outcome involved a meta‐analysis of four studies and in each of these the experimental group dressing regimen consisted of a primary PMM dressing plus a non‐PMM secondary dressing, and the control group had the same non‐PMM dressing as its primary dressing. Conversely, two studies for the short‐term (4 to 8‐week) healing outcome compared a PMM‐containing dressing with an advanced dressing. The long‐term outcome (and the time‐to‐event data) involved a study in which the experimental group received a PMM‐alginate combination dressing and the control group received an alginate dressing. One study in 117 participants potentially allowed us to investigate the appropriateness of the 'class' assumption, randomising head‐to‐head two different types of PMM dressing. However, the evidence was of very low certainty and we could not draw conclusions. We cannot be confident from the low‐certainty evidence that there are differences between healing outcomes at different durations, but even if the differences are real, we cannot determine if they are a consequence of the different types of comparison, the duration of follow‐up, the certainty of the evidence, or some other factor. </p> <p>All the identified studies were industry funded, but there were insufficient studies to examine publication bias statistically. We obtained results from the authors of two conference abstracts, one of which had not been published for 10 years (<a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a>) and the other for nearly 20 years (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>). The addition of one of these studies to the meta‐analysis for medium‐term healing reduced the effect estimate from RR 1.46 (95% CI 0.99 to 2.15) to 1.28 (95% CI 0.95 to 1.71) and smaller effects at the same interim time point were also found for the other study. These additional data do not affect the qualitative finding of a potential benefit in the medium term of using PMM‐containing dressing regimens, but they do imply a lack of robustness in the current evidence and the need for a large trial with outcomes measured at appropriate intervals in order to examine the overall effect of PMM treatments. </p> <p>Overall, we cannot be confident that the application of any dressing that claims to be protease‐modulating will lead to benefits in healing, neither can we be sure that our consideration of all PMM dressings as a 'class' has not diluted the effectiveness of a particular dressing. The 'class' assumption may not be reasonable and generalisability of the results to all PMM dressings may not be appropriate. </p> </section> <section id="CD011918-sec-0102"> <h3 class="title" id="CD011918-sec-0102">Quality of the evidence</h3> <p>The evidence in this review is marked by uncertainty, not only because of its sparsity, but also because of risk of bias. </p> <p>The evidence is of low or very low certainty for all outcomes. This is because of high risk of bias for outcomes in most studies, particularly regarding a lack of blinding of outcome assessors and also attrition bias. In addition, studies were small, with numerically few events, which gives rise to imprecision in the pooled effect estimates for healing. </p> <p>As discussed above, the meta‐analysis for medium‐term healing is sensitive to the addition of new studies. There is insufficient evidence to carry out sensitivity analyses on the basis of risk of bias or to investigate heterogeneity using subgroups, and publication bias could not be investigated. </p> </section> <section id="CD011918-sec-0103"> <h3 class="title" id="CD011918-sec-0103">Potential biases in the review process</h3> <p>We carefully defined PMM treatments to be those specifically marketed as having protease‐modulating activity, with this being a key feature of the product, or if no commercial product was named, we examined whether the study reported a specific intent of modulating proteases. This meant that a number of studies were excluded because of the interventions, even though matrix dressings were described (but without an indication of protease‐reducing mechanisms). It was important to have a clear and transparent definition of the class, and this definition was derived with important clinical input. This is not so much a potential bias, but a position with which others may disagree, however, inclusion of other studies may have affected the results. </p> </section> <section id="CD011918-sec-0104"> <h3 class="title" id="CD011918-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>Evidence on PMM treatments for healing VLUs is sparse: one systematic review investigated one type of PMM dressing (collagen oxidised regenerated cellulose) in people with venous, arterial and pressure ulcers (<a href="./references#CD011918-bbs2-0087" title="GaleaE . Managing chronic/stalled arterial, venous and pressure ulcers with collagen and oxidised regenerated cellulose dressings. 2015. www.worldwidewounds.com/2015/August/Galea/wounds‐galea.html (accessed 05 May 2016). ">Galea 2015)</a>. Two studies were identified for VLUs, one of which was excluded from our review (<a href="./references#CD011918-bbs2-0070" title="WollinaU , SchmidtW , KronertC , NelskampC , ScheibeA , FasslerD . Some effects of a topical collagen‐based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations. International Journal of Lower Extremity Wounds2005;4(4):214‐24. ">Wollina 2005</a>). Overall, the review concluded that, "although there is some evidence to support the use of collagen ORC, there is a clear need for further evidence". We have been unable to identify any further systematic reviews on PMM treatments. </p> <p>An overview of reviews of treatments for VLU has recently been published (<a href="./references#CD011918-bbs2-0113" title="NelsonEA , AdderleyU . Venous leg ulcers. Systematic review 1902. January 2016. clinicalevidence.bmj.com/x/systematic‐review/1902/overview.html (accessed 8 July 2016). ">Nelson 2016</a>), but does not report on PMM treatments. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011918-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011918-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011918-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011918-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 1 Proportion of participants healed (short term ‐ 8 weeks)." data-id="CD011918-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 1 Proportion of participants healed (short term ‐ 8 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 2 Proportion of participants healed (medium term ‐ 12 weeks)." data-id="CD011918-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 2 Proportion of participants healed (medium term ‐ 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 3 Proportion of participants with 1 or more adverse events at 2‐12 weeks." data-id="CD011918-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 3 Proportion of participants with 1 or more adverse events at 2‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 4 Proportion of participants with pain at 2‐12 weeks." data-id="CD011918-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 4 Proportion of participants with pain at 2‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 5 Proportion of participants with infection at 2‐12 weeks." data-id="CD011918-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 5 Proportion of participants with infection at 2‐12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 6 Sensitivity analysis ‐ available case ‐ proportion of participants healed." data-id="CD011918-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 6 Sensitivity analysis ‐ available case ‐ proportion of participants healed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011918-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/urn:x-wiley:14651858:media:CD011918:CD011918-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_t/tCD011918-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 7 Subgroup analysis: (+/‐) silver ‐ proportion of participants healed medium term." data-id="CD011918-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 PPM dressing regimen versus other dressing regimen, Outcome 7 Subgroup analysis: (+/‐) silver ‐ proportion of participants healed medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/media/CDSR/CD011918/image_n/nCD011918-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011918-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Protease‐modulating matrix dressing regimen compared to any other dressing regimen for healing venous leg ulcers</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Protease‐modulating matrix dressing compared to advanced dressings/no dressing for venous leg ulcers</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with venous leg ulcers<br/> <b>Intervention:</b> PMM dressing regimen<br/> <b>Comparison:</b> other dressing regimen; different comparators across studies </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Absolute effect<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other dressing regimen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PMM dressing regimen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>TIme to complete healing</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Estimated median time to complete healing: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Estimated median time to complete healing: 4.5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.21<br/> (0.74 to 1.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>100<br/> (1 RCT<sup>ǂ</sup>) </p> <p>66 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Difference in estimated median time to complete healing: approximately 1.5 months shorter</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants healed ‐ short term (4‐8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>287 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>210 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/> (0.34 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>207<br/> (2 RCTs) </p> <p>21 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 77 fewer wounds healed per 1000</b> </p> <p>(95% CI 167 more to 190 fewer)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants healed ‐ medium term (12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>512 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/> (0.95 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>192<br/> (4 RCTs) </p> <p>89 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 112 more wounds healed per 1000</b> </p> <p>(95% CI 20 fewer to 284 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants healed ‐ long term (over 24 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>678 per 1000<br/> (512 to 902) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.80 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/> (1 RCT<sup>ǂ</sup>) </p> <p>66 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Difference: 38 more wounds healed per 1000</b> </p> <p>(95% CI 128 fewer to 262 more)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants with 1 or more adverse events at 2‐12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>172 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>178 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.75 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>363<br/> (5 RCTs) </p> <p>99 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Difference: 6 more adverse events per 1000</b> </p> <p>(95% CI 43 fewer to 72 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk without the intervention is based on the median control group risk across studies. The corresponding risk with the intervention (and the 95% confidence interval for the difference) is based on the overall relative effect (and its 95% confidence interval). </p> <p><sup>ǂ</sup> Same study (<a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a>)<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High:</b> It is very likely that the effect will be close to what was found in the research. </p> <p><b>Moderate:</b> It is likely that the effect will be close to what was found in the research, but there is a possibility that it will be substantially different. </p> <p><b>Low:</b> It is likely that the effect will be substantially different from what was found in the research, but the research provides an indication of what might be expected. </p> <p><b>Very low:</b> The anticipated effect is very uncertain and the research does not provide a reliable indication of what might be expected </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Imprecision (downgraded twice): 66 events, wide CI; assumptions in calculation of HR ‐ no censoring (not downgraded); data extracted from graph (not downgraded) </p> <p><sup>2</sup> Risk of bias (downgraded once): majority of information at high risk of bias. Imprecision (downgraded twice): 21 events and wide CI </p> <p><sup>3</sup> Risk of bias (downgraded once): majority of information at high risk of bias. Imprecision (downgraded once): 89 events, CI consistent with no effect and benefit </p> <p><sup>4</sup> Imprecision (downgraded twice): 66 events, wide CI around absolute effect </p> <p><sup>5</sup> Risk of bias (not downgraded): majority of information at low risk of bias. Imprecision (downgraded twice): 99 events, CI wide around relative effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Protease‐modulating matrix dressing regimen compared to any other dressing regimen for healing venous leg ulcers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011918-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Comparison type*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Intervention group</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary dressing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Secondary dressing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary dressing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Secondary dressing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basic wound contact</p> <p>(BWC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silverR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM + BWC</p> <p>(interfacial dressing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrocolloid‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydrogel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BWC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐alginateE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM‐silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PMM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>* Comparison types:</p> <p>1. PMM dressing regimen versus basic wound contact dressing regimen</p> <p>2a. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group the same as the primary dressing in the control group </p> <p>2b. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group being similar but different from the primary dressing in the control group </p> <p>2c. PMM dressing regimen versus advanced dressing regimen with the same secondary dressings in both groups or no secondary dressings or secondary dressings only in the control group </p> <p>2d. PMM dressing regimen versus advanced dressing regimen: PMM/advanced combination dressing versus advanced dressing </p> <p>3. PMM dressing 1 versus PMM dressing 2</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011918-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison type*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions (dressings)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Length of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion healed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to healing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion with pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion with infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resource use</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0001" title="AndriessenA , PolignanoR , AbelM . Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. Journal of Wound Care2009;18(4):145‐6, 148. ">Andriessen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a and 2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + foam (n = 4);</p> <p>Group 2: foam (n = 4)</p> <p>Group 3: basic wound contact (n = 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/4 Group 2: 0/4 Group 3: 0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/4 Group 2: 0/4 Group 3: 4/4</p> <p>Peto OR for 1 vs 3: 0.03 (95% CI 0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0002" title="CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcome. woundchek.com/uploads/downloads/posters_articles/Targeted‐Use‐of‐CollagenORC‐Improves‐Clinical‐Outcome.pdf (accessed 5 January 2016). CullenB , GibsonM , NisbetL . Targeted use of collagen/ORC improves clinical outcomes. Wound Repair and Regeneration2012;20(5):A93. ">Cullen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM1 (n = 32);</p> <p>Group 2: PMM2 (n = 32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0003" title="HanftJ , SerenaT , SnyderR . Evaluation of the clinical effectiveness of a collagen‐ORC antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association. 2006 May 18‐20; Prague, Czech Republic. 2006:151. HanftJR , SerenaT , SnyderR . A study to evaluate the clinical effectiveness of a Collagen‐ORC Antimicrobial Matrix in venous leg ulcers. Wound Repair and Regeneration2006;14(2):A64. ">Hanft 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐silver + hydrocolloid (n = 22);</p> <p>Group 2: hydrocolloid (n = 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks and 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks Group 1: 5/22</p> <p>Group 2: 3/27</p> <p>RR 2.05 (95% CI 0.55 ‐ 7.63)</p> <p>12 weeks </p> <p>Group 1: 14/22</p> <p>Group 2:</p> <p>16/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No results reported (though in protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No results reported (though in protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No results reported (though in protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0004" title="HumbertP , FaivreB , VeranY , DebureC , TruchetetF , BecherelPA , et al. Protease‐modulating polyacrylate‐based hydrogel stimulates wound bed preparation in venous leg ulcers: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2013;28(12):1742‐50. ">Humbert 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM (n = 34);</p> <p>Group 2: hydrogel (n = 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 15/34</p> <p>Group 2: 18/41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 7/32</p> <p>Group 2: 0/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/32</p> <p>Group 2: 2/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0005" title="LanzaraS , TacconiG , GianesiniS , MenegattiE , FedericiF , LiboniA , et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers. EWMA Journal2008;8(2 Suppl):76. ">Lanzara 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐silver + foam (n = 15);</p> <p>Group 2: foam (n = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 11/15</p> <p>Group 2: 7/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 4/15</p> <p>Group 2: 5/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0006" title="ManizateF , FullerA , GendicsC , LantisJC . A prospective, single‐center, nonblinded, comparative, postmarket clinical evaluation of a bovine‐derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable‐etiology, bilateral lower‐extremity wounds. Advances in Skin and Wound Care2012;25(5):220‐5. ">Manizate 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐silver (n = 10);</p> <p>Group 2: hydrocolloid + silver (n = 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 3/10</p> <p>Group 2: 5/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/10</p> <p>Group 2: 0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0007" title="AugustinM , HerbergerK , KroegerK , MuenterKC , GoepelL , RychlikR . Cost‐effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. International Wound Journal2016;13:82–7. MeaumeS , TruchetetF , CambazardF , LokC , DebureC , DalacS , et al. A randomized, controlled, double‐blind prospective trial with a Lipido‐Colloid Technology‐Nano‐Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8;Toronto, Canada2012;20(4):500‐11. ">Meaume 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐foam (n = 93);</p> <p>Group 2: foam (n = 94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 6/93</p> <p>Group 2: 7/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 29/89</p> <p>Group 2: 27/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 1/89 Group 2: 1/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 7/89</p> <p>Group 2: 6/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EQ‐5D:</b> </p> <p>Pain/discomfort:</p> <p>Group 1: mean 1.53 (SD 0.53) n = 89</p> <p>Group 2: 1.74 (0.65) n = 88</p> <p>MD: ‐0.21 (95% CI ‐0.38 to ‐0.04)</p> <p>Anxiety/depression:</p> <p>1.35 (0.53) and 1.54 (0.60)</p> <p>MD: ‐0.19 (95% CI ‐0.36 to ‐0.02) numbers analysed assumed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean total treatment costs over 8 weeks (Germany):</p> <p>Group 1: EUR 557.51</p> <p>Group 2: EUR 526.19</p> <p>Cost effectiveness analysis was based on number with at least 40% wound area reduction and so are not reported here </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0008" title="PetkovL . A comparative study of the influence of two topical wound dressings used during healing on subsequent venous ulcer recurrence. 6th European Conference on Advances in Wound Management: Wound Healing Therapy: a critique of current practice and opportunities for improvement; 1996 October 1‐4 October; Amsterdam, Netherlands. 1997:267. ">Petkov 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM‐alginate</p> <p>Group 2: alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months: Group 1: 34/50</p> <p>Group 2:</p> <p>32/50</p> <p>RR: 1.06 (95% CI 0.80 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graph of cumulative number of healed ulcers. HR calculated (<a href="./references#CD011918-bbs2-0136" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(16). [DOI: 10.1186/1745‐6215‐8‐16] ">Tierney 2007</a>): 1.21 (95% CI 0.75 to 1.97), assuming no censoring </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL/Resources not reported.</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Number healed at other times (from graph); 50 randomised per group):</p> <p>1 month: 2 and 0</p> <p>2 months: 12 and 8</p> <p>3 months: 26 and 20</p> <p>4 months: 29 and 22</p> <p>5 months: 34 and 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0009" title="RomanelliM , MulderG , PaggiB , MacchiaM , PanduriS , DiniV . The use of a collagen matrix in hard‐to‐heal venous leg ulcers. Journal of Wound Care2015;24(11):543‐7. ">Romanelli 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + basic wound contact dressing + alginate (n = 20);</p> <p>Group 2: alginate (n = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 6/20 Group 2: 5/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/20</p> <p>Group 2: 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/20 Group 2: 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0010" title="DompmartinA , SchmutzJL , CollierM , SmithJ , BohbotS . Management of venous leg ulcers with two active wound dressings. Protocol of a randomized clinical trial. 17th Conference of the European Wound Management Association; 2007 May 2‐4; Glasgow, Scotland. 2007:55. MeaumeS , DompmartinA , SchmutzJ‐L , OurabahZ , ThirionV . Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 18th Conference of the European Wound Management Association; 2008 May 14‐16; Lisbon, Portugal. 2008; Vol. 8, issue 2 Suppl:Abstract 38. MeaumeS , SchmutzJ‐L , DompmartinA , FaysS , OurabahZ , ThirionV , et al. Management of venous leg ulcers with two active wound dressings. Results of a randomized clinical trial. 3rd Congress of the World Union of Wound Healing Societies meeting; 2008 June 4‐8; Toronto, Canada. 2008:Abstract OR047. SchmutzJ‐L , MeaumeS , FaysS , OurabahZ , GuillotB , ThirionV , et al. Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal2008;5(2):172‐82. ">Schmutz 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM1 (n = 57);</p> <p>Group 2: PMM2 (n = 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 10/57</p> <p>Group 2: 8/60</p> <p>RR: 1.32 (95% CI 0.56 to 3.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 14/46</p> <p>Group 2: 23/49</p> <p>RR: 0.65 (95% CI 0.38 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 4/40</p> <p>Group 2: 12/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 1/40</p> <p>Group 2: 6/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0011" title="SmeetsR , UlrichD , UnglaubF , WöltjeM , PalluaN . Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal2008;5(2):195‐203. ">Smeets 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + hydrocolloid (n = 17);</p> <p>Group 2: hydrocolloid (n = 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011918-bbs2-0012" title="DelchambreJ . Venous leg ulcers trials. Journal of Wound Care2002;12(3 Suppl):6‐7. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Journal of Wound Care2002;11(9):335‐41. VinF , TeotL , MeaumeS . The healing properties of Promogran in venous leg ulcers. Phlebologie2003;56(1):77‐86. ">Vin 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PMM + basic wound contact dressing (n = 37);</p> <p>Group 2: basic wound contact dressing (n = 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 18/37</p> <p>Group 2: 12/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 5/30 Group 2: 5/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe pain:</p> <p>Group 1: 6/27</p> <p>Group 2: 3/24</p> <p>Constant pain: Group 1: 7/27 Group 2: 4/24</p> <p>RR: 1.56 (95% CI 0.52 to 4.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: 0/27</p> <p>Group 2: 5/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saline vials per treatment: <br/> Group 1: mean 1.06 (SD 0.78)<br/> Group 2: mean 1.27 (SD 0.78) </p> <p>MD: ‐0.21 (95% CI ‐0.31 to ‐0.11)</p> <p>Number of gauzes: </p> <p>Group 1: 3.8 (2.5)</p> <p>Group 2: 3.7 (2.2)</p> <p>MD: 0.10 (95% CI ‐0.17 to 0.37)</p> <p>(SD 201) seconds</p> <p>MD: ‐40.0 (95% CI ‐128.9 to 48.9)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>* Comparison types:</p> <p>1. PMM dressing regimen versus basic wound contact dressing regimen</p> <p>2a. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group the same as the primary dressing in the control group </p> <p>2b. PMM dressing regimen versus advanced dressing regimen with the secondary dressing in the experimental group being similar but different from the primary dressing in the control group </p> <p>2c. PMM dressing regimen versus advanced dressing regimen with the same secondary dressings in both groups or no secondary dressings or secondary dressings only in the control group </p> <p>2d. PMM dressing regimen versus advanced dressing regimen: PMM/advanced combination dressing versus advanced dressing </p> <p>3. PMM dressing 1 versus PMM dressing 2</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/full#CD011918-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011918-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PPM dressing regimen versus other dressing regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants healed (short term ‐ 8 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.34, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PMM versus foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.30, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PMM‐silver versus hydrocolloid/silver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.19, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants healed (medium term ‐ 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.95, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PMM + BWC versus BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.83, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 PMM + BWC + alginate versus alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.44, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 PMM‐silver + foam versus foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.84, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 PMM‐silver + hydrocolloid versus hydrocolloid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.69, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of participants with 1 or more adverse events at 2‐12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.75, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Short term (2‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.75, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Medium term (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.31, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of participants with pain at 2‐12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PMM versus hydrogel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PMM + foam versus foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 PMM + foam versus BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 PMM versus foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 PMM + BWC versus BWC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 PMM + BWC + alginate versus alginate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proportion of participants with infection at 2‐12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.29, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PMM versus hydrogel (2 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PMM‐silver versus hydrocolloid + silver (8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 PMM versus foam (8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.40, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 PMM + BWC versus BWC (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 PMM‐silver + foam versus foam (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.27, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sensitivity analysis ‐ available case ‐ proportion of participants healed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Short term (4‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.33, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Medium term (12 weeks all studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.96, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Long term (over 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.80, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Subgroup analysis: (+/‐) silver ‐ proportion of participants healed medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Silver in PMM arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.85, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 No silver in PMM arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.85, 2.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PPM dressing regimen versus other dressing regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011918.pub2/references#CD011918-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011918.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011918-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011918-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011918-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011918-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD011918-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011918\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011918\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011918\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011918\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011918\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011918.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011918.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011918.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011918.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011918.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716372132"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011918.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716372136"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011918.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9de2eb389368',t:'MTc0MDcxNjM3Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 